

Publikationsliste „Krebsregisterdaten“ – Stand 31.12.2025

1. Crocetti E, Bennett D, Jooste V, Rossi S, Maso LD, Marcos-Gragera R, et al. Skin melanoma survival is improving in Europe but regional differences persist: Results of the EURO CARE-6 study. *Eur J Cancer*. 2025 Dec 9;231:116061.
2. Völkel V, Gerken M, Kleihues-van Tol K, Schoffer O, Bierbaum V, Bobeth C, et al. Long-term survival after treatment in certified lung cancer centers and not certified hospitals: Results of a large German cohort study using clinical routine data. *Gesundheitswesen*. 2025 Dec;87(S 03):S373–82.
3. Baden D, Wolgast N, Altrock PM, Steinhäuser S, Voran J, Beder T, et al. Epidemiology, survival, and treatment of acute myeloid and lymphoblastic leukaemia in Germany: a nationwide population-based registry analysis. *Lancet Reg Health Eur*. 2025 Dec;59:101503.
4. Wolgast N, Amelunxen E, Fransecky L, Altrock P, Beder T, Ronnacker J, et al. Epidemiology and survival of patients with T-cell prolymphocytic leukemia. *Blood Cancer J*. 2025 Nov 24;15(1):206.
5. Tinhofer I, Hofmann E, Trelinska-Finger A, Saraei T, Keilholz U, Heiland M, et al. Trends and efficacy of definitive radiotherapy regimens for locally advanced head and neck cancer in elderly patients: A population-based analysis by the German cancer registry group. *Eur J Cancer*. 2025 Nov 17;230:116039.
6. Müller JA, Bedir A, Katalinic A, Oesterling F, Graw A, Kluttig A, et al. Research with cancer registry data in radiation oncology-current possibilities and perspectives : A narrative review. *Strahlenther Onkol*. 2025 Nov 10;
7. Hansinger J, Schoffer O, Völkel V, Gerken M, Wimberger P, Bierbaum V, et al. Comparison of survival in ovarian cancer patients following treatment in certified gynecologic oncology centers and non-certified hospitals: a German retrospective cohort study (WiZen). *J Ovarian Res*. 2025 Nov 4;18(1):238.
8. Botta L, Capocaccia R, Bernasconi A, Rossi S, Galceran J, Dal Maso L, et al. The impact of cancer survivors' extra risk of noncancer mortality on net survival estimation. *Am J Epidemiol*. 2025 Nov 4;194(11):3316–24.
9. Elsner SA, Haußmann E, Grieger P, Hadwiger M, Rieck A, Hacker A, et al. Optimising breast cancer screening in national mammography screening centres: challenges and insights on implementing additional ultrasound for women with dense breast tissue - a qualitative study. *BMC Cancer*. 2025 Oct 31;25(1):1684.
10. Bertram S, Schliemann A, Katalinic A, Kim-Wanner SZ, Pritzkuleit R, Twardella D, et al. Overall survival and progression-free survival of patients with non-small cell lung cancer and either limited or extensive synchronous metastatic spread in Germany-a population-based cancer registry cohort study. *Transl Lung Cancer Res*. 2025 Oct 31;14(10):4436–48.

11. Bertram S, Schliemann A, Katalinic A, Kim-Wanner SZ, Pritzkuleit R, Twardella D, et al. Characteristics of patients with non-small cell lung cancer and either limited or extensive synchronous metastatic spread in Germany-a population-based cancer registry cohort study. *Transl Lung Cancer Res.* 2025 Oct 31;14(10):4422–35.
12. Soff J, Benz SR, Kowalski C, Hansinger J, Gerken M, Maier D, et al. Heterogeneity of treatment preferences in the absence of guideline recommendations - a case vignette study in colorectal cancer tumor boards in Germany, Austria and Switzerland. *BMC Gastroenterol.* 2025 Oct 7;25(1):700.
13. Schmelter F, Schröder T, Laumonnier Y, Bischoff SC, Derer S, Jensen BAH, et al. Impaired glucose metabolism in irritable bowel syndrome: personalised low-glycaemic diet as potential therapeutic target. *Gut.* 2025 Oct 5;gutjnl-2025-336797.
14. Wiegers NC, Germer S, Rudolph C, Rath N, Rausch K, Katalinic A, et al. Evaluating Imputation Techniques for Survival Data Utilizing Kaplan-Meier Curves. *Stud Health Technol Inform.* 2025 Oct 2;332:17–21.
15. Fisse AL, Bonberg N, Beuker C, Pfeuffer C, Heidenreich A, Krüger C, et al. Disease Characteristics and Treatments Associated with Outcome in Primary Angiitis of the Central Nervous System-A Multicenter Cohort Study in 163 Patients. *Ann Neurol.* 2025 Oct;98(4):883–93.
16. Duhn J, von Fritsch L, Honselmann KC, Bolm L, Gerling C, Tol KK van, et al. Oncologic outcomes and prognostic factors of colloid carcinoma of the pancreas - a retrospective real-world data analysis from the German cancer registry group of the society of German tumor centers. *Langenbecks Arch Surg.* 2025 Sept 23;410(1):275.
17. Langheinrich M, Gerken M, Robers G, Hansinger J, Franke B, Lacruz ME, et al. Survival benefit of adjuvant chemotherapy in elderly patients with UICC stage III colon carcinoma: A 20-year population-based German cohort study. *Eur J Cancer.* 2025 Sept 9;227:115583.
18. Kusche H, Gundler C, Johanns O, Sauerberg M, Wicker T, Heinrichs V, et al. Leveraging machine-learning techniques to detect recurrences in cancer registry data: A multi-registry validation study using German lung cancer data. *Eur J Cancer.* 2025 Sept 9;227:115604.
19. Tetzlaff F, Barnes B, Jansen L, Peters F, Schultz A, Katalinic A, et al. Widening socioeconomic inequalities in cancer incidence and related potential to reduce cancer between 2008 and 2019 in Germany. *Sci Rep.* 2025 Sept 1;15(1):32232.
20. Hoogendijk R, Capocaccia R, van der Lugt J, Kranendonk MEG, Hoving EW, Wesseling P, et al. Long-term survival and cure fraction estimates for paediatric central nervous system tumours in 31 European countries (EUROCARE-6): a population-based study. *Lancet Oncol.* 2025 Aug;26(8):1091–9.
21. Doll C, Hofmann E, Trelinska-Finger A, Heiland M, Letsch A, Knödler M, et al. Benefit from adjuvant radiotherapy in early-stage oral cavity and oropharyngeal cancer with solitary

ipsilateral lymph node metastasis - A population-based study on German cancer registry data. *Oral Oncol.* 2025 Aug;167:107384.

22. Bernasconi A, Toss A, Zattarin E, Mousavi SM, Blum M, Kuehni CE, et al. Prognosis of Breast Cancer in European female adolescents and young adults (AYAs): EUROCARE-6 retrospective cohort results. *Breast.* 2025 Aug;82:104472.
23. von Fritsch L, Duhn J, Abdalla TSA, Honselmann KC, Bolm L, Braun R, et al. An R0 resection margin does improve overall survival after PDAC resection- real-world evidence from 6.000 cases from the German Cancer Registry Group. *Eur J Surg Oncol.* 2025 June;51(6):109693.
24. Duhn J, Strässer J, von Fritsch L, Braun R, Honselmann KC, Kist M, et al. Adjuvant Chemotherapy Is Associated with Improved Survival in Advanced Ampullary Adenocarcinoma-A Population-Based Analysis by the German Cancer Registry Group. *J Clin Med.* 2025 May 30;14(11).
25. Greystoke A, Daumont MJ, Rault C, Baltus H, Ding PQ, Emanuel G, et al. Real-world treatment patterns and outcomes for patients with non-metastatic non-small cell lung cancer: retrospective analyses in Canada, England, and Germany. *BMC Pulm Med.* 2025 May 27;25(1):265.
26. Germer S, Rudolph C, Katalinic A, Rath N, Rausch K, Handels H. Lung Cancer Survival Estimation Using Data from Seven German Cancer Registries. *Stud Health Technol Inform.* 2025 May 15;327:457–61.
27. Rutsch M, Mischnik A, Katalinic A, Deck R. [Regional Healthcare Situation and Needs of Former SARS-CoV-2 Infected Persons in the Hanseatic City of Lübeck - Results of a Population Survey]. *Gesundheitswesen.* 2025 May;87(5):344–52.
28. Duhn J, von Fritsch L, Bolm L, Braun R, Honselmann K, Litkevych S, et al. Perioperative and oncologic outcomes after total pancreatectomy and pancreatoduodenectomy for pancreatic head adenocarcinoma-A propensity score-matched analysis from the German Cancer Registry Group. *Surgery.* 2025 May;181:109292.
29. Tasdogan A, Sullivan RJ, Katalinic A, Lebbe C, Whitaker D, Puig S, et al. Cutaneous melanoma. *Nat Rev Dis Primers.* 2025 Apr 3;11(1):23.
30. Indini A, Didoné F, Massi D, Puig S, Casadevall JR, Bennett D, et al. Corrigendum to ‘Incidence and prognosis of cutaneous melanoma in European adolescents and young adults (AYAs): EUROCARE-6 retrospective cohort results’ [Eur J Cancer 213 (2024):115079]. *Eur J Cancer.* 2025 Mar 11;218:115295.
31. Schnoor M, Heidenreich A, Jürgensen M, Döhnert U, Hiort O, Katalinic A. Satisfaction with health care among people with differences of sex development (DSD) in Germany. *Endocr Connect.* 2025 Mar 1;14(3).

32. Eisemann N, Bunk S, Mukama T, Baltus H, Elsner SA, Gomille T, et al. Nationwide real-world implementation of AI for cancer detection in population-based mammography screening. *Nat Med*. 2025 Mar;31(3):917–24.
33. Di Carlo V, Eberle A, Stiller C, Bennett D, Katalinic A, Marcos-Gragera R, et al. Sex differences in survival from melanoma of the skin: The role of age, anatomic location and stage at diagnosis: A CONCORD-3 study in 59 countries. *Eur J Cancer*. 2025 Feb 25;217:115213.
34. Lacruz ME, Thies S, Schmidt-Pokrzywniak A, Wittenberg I, Engler T, Reinwald F, et al. Clinical characteristics, metastasis patterns, and treatment outcomes of HER2-low breast cancer. *Sci Rep*. 2025 Feb 7;15(1):4584.
35. Trama A, Bernasconi A, Cañete A, Carulla M, Daubisse-Marliac L, Rossi S, et al. Incidence and survival of rare adult solid cancers in Europe (EUROCARE-6): A population-based study. *Eur J Cancer*. 2025 Jan;214:115147.
36. Baltus H, Hübner J, Garbe C, Hagenström K, Rohr M, Hischke S, et al. Evaluation of skin cancer screening in Germany - a Microsimulation. *J Dtsch Dermatol Ges*. 2025 Jan;23(1):19–27.
37. Jürgensen M, Jürgensen M, Rapp M, Schnoor M, Heidenreich A, Döhnert U, et al. Development of Quality Indicators to Evaluate the Quality of Care for People with Differences of Sex Development. *Horm Res Paediatr*. 2025;98(6):699–708.
38. Manz K, Weitmann K, Theen S, Robers G, Pritzkeleit R, Katalinic A, et al. Cancer incidence and mortality in the occupational cohort of a German toxic waste landfill: a retrospective cohort study. *BMC Public Health*. 2024 Dec 22;24(1):3560.
39. Schnoor M, Heidenreich A, Jürgensen M, Döhnert U, Hiort O, Katalinic A. Quality of care for people with differences of sex development (DSD) in Germany. *Orphanet J Rare Dis*. 2024 Dec 9;19(1):460.
40. Indini A, Didoné F, Massi D, Puig S, Casadevall JR, Bennett D, et al. Incidence and prognosis of cutaneous melanoma in European adolescents and young adults (AYAs): EUROCARE-6 retrospective cohort results. *Eur J Cancer*. 2024 Dec;213:115079.
41. Germer S, Rudolph C, Labohm L, Katalinic A, Rath N, Rausch K, et al. Survival analysis for lung cancer patients: A comparison of Cox regression and machine learning models. *Int J Med Inform*. 2024 Nov;191:105607.
42. Virgili G, Capocaccia R, Botta L, Bennett D, Hadjistilianou T, Innos K, et al. Survival and Health Care Burden of Children With Retinoblastoma in Europe. *JAMA Ophthalmol*. 2024 Oct 10;142(11):1062–70.
43. Hansinger J, Völkel V, Gerken M, Schoffer O, Wimberger P, Bierbaum V, et al. Endometrial Cancer - Long-Term Survival in Certified Cancer Centers and Non-Certified

Hospitals: Comparative Analysis Based on a Large German Retrospective Cohort Study (WiZen). *Geburtshilfe Frauenheilkd.* 2024 Oct;84(10):979–88.

44. Erikson K, Heidenreich A, Labunska V, Beach R, Cremers F, Rades D, et al. Evaluation of ocular and systemic endpoints after radiation of posterior uveal melanoma - A systematic review and meta-analysis. *Heliyon.* 2024 Sept 30;10(18):e36468.
45. Schmidt H, Baust K, Calaminus G, Hohls L, Tetzner K, Griech N, et al. Effectiveness of structured, multidisciplinary long-term care for pediatric cancer survivors: protocol of the multicenter, randomized-controlled AELKI study. *Trials.* 2024 Sept 8;25(1):597.
46. Bouvier AM, Jooste V, Lillini R, Marcos-Gragera R, Katalinic A, Giorgi Rossi P, et al. Differences in survival and recurrence of colorectal cancer by stage across population-based European registries. *Int J Cancer.* 2024 Sept 1;155(5):807–15.
47. Grieger P, Eisemann N, Hammersen F, Rudolph C, Katalinic A, Waldmann A. Initial Evidence of a Possible Effect of HPV Vaccination on Cancer Incidence in Germany—Focus on Cervical Cancer. *Dtsch Arztebl Int.* 2024 June 28;121(13):415–21.
48. Schulz NA, Carus J, Wiederhold AJ, Johanns O, Peters F, Rath N, et al. Learning debiased graph representations from the OMOP common data model for synthetic data generation. *BMC Med Res Methodol.* 2024 June 22;24(1):136.
49. Weigel S, Katalinic A. [Structured screening for sporadic breast cancer]. *Radiologie (Heidelb).* 2024 June;64(6):463–70.
50. Sant M, Vener C, Lillini R, Rossi S, Bonfarnuzzo S, Marcos-Gragera R, et al. Long-term survival for lymphoid neoplasms and national health expenditure (EUROCARE-6): a retrospective, population-based study. *Lancet Oncol.* 2024 June;25(6):731–43.
51. Papathemelis T, Ortmann O, Kohl C, Neuser P, Tol KK van, Klinkhammer-Schalke M, et al. Treatment of endometrial cancer from 2000 to 2020 in Germany: a retrospective population based cohort study. *J Cancer Res Clin Oncol.* 2024 May 27;150(5):279.
52. Abdalla TSA, Duhn J, Klinkhammer-Schalke M, Zeissig SR, Kleihues-van Tol K, Honselmann KC, et al. Oncological Outcomes and Patterns of Recurrence after the Surgical Resection of an Invasive Intraductal Papillary Mucinous Neoplasm versus Primary Pancreatic Ductal Adenocarcinoma: An Analysis from the German Cancer Registry Group of the Society of German Tumor Centers. *Cancers (Basel).* 2024 May 26;16(11).
53. Trama A, Botta L, Stiller C, Visser O, Cañete-Nieto A, Spycher B, et al. Survival of European adolescents and young adults diagnosed with cancer in 2010-2014. *Eur J Cancer.* 2024 May;202:113558.
54. Petruch N, Servin Rojas M, Lillemoe KD, Castillo CFD, Braun R, Honselmann KC, et al. The impact of surgical-oncologic textbook outcome in patients with stage I to III pancreatic ductal adenocarcinoma: A cross-validation study of two national registries. *Surgery.* 2024

Apr;175(4):1120–7.

55. Schumann L, Hadwiger M, Eisemann N, Katalinic A. Lead-Time Corrected Effect on Breast Cancer Survival in Germany by Mode of Detection. *Cancers (Basel)*. 2024 Mar 28;16(7).
56. Peters E, Schmidt H, Baltus H, Schnoor M, Hartmann N, Katalinic A. [Social pediatric care situation and needs during the COVID-19 pandemic from 2020 to 2022. What is needed now?]. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz*. 2024 Mar;67(3):351–61.
57. De Angelis R, Demuru E, Baili P, Troussard X, Katalinic A, Chirlaque Lopez MD, et al. Complete cancer prevalence in Europe in 2020 by disease duration and country (EUROCARE-6): a population-based study. *Lancet Oncol*. 2024 Mar;25(3):293–307.
58. Lupo PJ, Chambers TM, Mueller BA, Clavel J, Dockerty JD, Doody DR, et al. Nonchromosomal birth defects and risk of childhood acute leukemia: An assessment in 15 000 leukemia cases and 46 000 controls from the Childhood Cancer and Leukemia International Consortium. *Int J Cancer*. 2024 Feb 1;154(3):434–47.
59. Katalinic M, Schenk M, Franke S, Katalinic A, Neumuth T, Dietz A, et al. Generation of a Realistic Synthetic Laryngeal Cancer Cohort for AI Applications. *Cancers (Basel)*. 2024 Feb 1;16(3).
60. Schoffer O, Wimberger P, Gerken M, Bierbaum V, Bobeth C, Rößler M, et al. Treatment in Certified Breast Cancer Centers Improves Chances of Survival of Patients with Breast Cancer: Evidence Based on Health Care Data from the WiZen Study. *Geburtshilfe Frauenheilkd*. 2024 Feb;84(2):153–63.
61. Lange B, Jaeger VK, Harries M, Rücker V, Streeck H, Blaschke S, et al. Estimates of protection levels against SARS-CoV-2 infection and severe COVID-19 in Germany before the 2022/2023 winter season: the IMMUNEBRIDGE project. *Infection*. 2024 Feb;52(1):139–53.
62. Carré J, Herzog B, Reil D, Schneider C, Pflüger M, Löbel M, et al. [Impact of the COVID-19 pandemic on the diagnosis and treatment of patients with head and neck cancer in Brandenburg and Berlin]. *HNO*. 2024 Feb;72(2):90–101.
63. Nanz L, Keim U, Katalinic A, Meyer T, Garbe C, Leiter U. Epidemiology of Keratinocyte Skin Cancer with a Focus on Cutaneous Squamous Cell Carcinoma. *Cancers (Basel)*. 2024 Jan 31;16(3).
64. De Angelis R, Demuru E, Baili P, Troussard X, Katalinic A, Chirlaque Lopez MD, et al. Complete cancer prevalence in Europe in 2020 by disease duration and country (EUROCARE-6): a population-based study. *Lancet Oncol*. 2024 Jan 30;S1470-2045(23)00646-0.

65. Eisemann N, Schumann L, Baltus H, Labohm L, Kraywinkel K, Katalinic A. Longer Survival From Melanoma in Germany. *Dtsch Arztebl Int.* 2024 Jan 26;121(2):45–51.
66. Eisemann N, Schumann L, Baltus H, Labohm L, Kraywinkel K, Katalinic A. Longer Survival From Melanoma in Germany: A Registry-Based Time Series Study. *Dtsch Arztebl Int.* 2024 Jan 26;(Forthcoming):arztebl.m2023.0242.
67. Abdalla TSA, Bolm L, Klinkhammer-Schalke M, Zeissig SR, Kleihues van Tol K, Bronsert P, et al. When Should Lymphadenectomy Be Performed in Non-Metastatic Pancreatic Neuroendocrine Tumors? A Population-Based Analysis of the German Clinical Cancer Registry Group. *Cancers (Basel).* 2024 Jan 19;16(2).
68. Scholz M, Horn K, Pott J, Wuttke M, Kühnapfel A, Nasr MK, et al. X-chromosome and kidney function: evidence from a multi-trait genetic analysis of 908,697 individuals reveals sex-specific and sex-differential findings in genes regulated by androgen response elements. *Nat Commun.* 2024 Jan 18;15(1):586.
69. Scobioala S, Parfitt R, Matulat P, Byrne J, Langer T, Troschel FM, et al. The impact of the temporal sequence of cranial radiotherapy and platin-based chemotherapy on hearing impairment in pediatric and adolescent CNS and head-and-neck cancer patients: A report from the PanCareLIFE consortium. *Int J Cancer.* 2024 Jan 15;154(2):320–31.
70. Schöttker B, Holleczeck B, Hybsier S, Köhrle J, Schomburg L, Brenner H. Strong associations of serum selenoprotein P with all-cause mortality and mortality due to cancer, cardiovascular, respiratory and gastrointestinal diseases in older German adults. *Eur J Epidemiol.* 2024 Jan 10;
71. Bierbaum V, Bobeth C, Roessler M, Gerken M, Tol KK van, Reissfelder C, et al. Treatment in certified cancer centers is related to better survival in patients with colon and rectal cancer: evidence from a large German cohort study. *World J Surg Oncol.* 2024 Jan 6;22(1):11.
72. Güven DC, Thong MS, Arndt V. Survivorship outcomes in patients treated with immune checkpoint inhibitors: a scoping review. *J Cancer Surviv.* 2024 Jan 4;
73. Scholz-Kreisel P, Becker C, Kaiser M, Mahmoudpour SH, Voigt M, Ressing M, et al. Subsequent primary neoplasms after childhood cancer therapy - design and description of the German nested case-control study STATT-SCAR. *Cancer Causes Control.* 2024 Jan;35(1):33–41.
74. Lugnier C, Sommerlatte S, Attenberger U, Beer AJ, Bentz M, Benz SR, et al. Prioritization and Resource Allocation in the Context of the COVID-19 Pandemic: Recommendations for Colorectal and Pancreatic Cancer in Germany. *Oncol Res Treat.* 2024;47(6):296–305.
75. Katalinic A, Noftz MR, Garcia-Velasco JA, Shulman LP, van den Anker JN, Strauss Iii JF. No additional risk of congenital anomalies after first-trimester dydrogesterone use: a systematic review and meta-analysis. *Hum Reprod Open.* 2024;2024(1):hoae004.

76. Katalinic A. Reply: Absence of evidence is not evidence of absence for first trimester dydrogesterone-induced birth defects. *Hum Reprod Open*. 2024;2024(2):hoae031.
77. Käding N, Waldeck F, Meier B, Boutin S, Borsche M, Balck A, et al. Influence of non-pharmaceutical interventions during the COVID-19 pandemic on respiratory viral infections - a prospective population-based cohort study. *Front Public Health*. 2024;12:1415778.
78. Petruch N, Servin Rojas M, Lillemoe KD, Castillo CFD, Braun R, Honselmann KC, et al. The impact of surgical-oncologic textbook outcome in patients with stage I to III pancreatic ductal adenocarcinoma: A cross-validation study of two national registries. *Surgery*. 2023 Dec 12;S0039-6060(23)00844-9.
79. Schwedhelm C, Nimptsch K, Ahrens W, Hasselhorn HM, Jöckel KH, Katzke V, et al. Chronic disease outcome metadata from German observational studies - public availability and FAIR principles. *Sci Data*. 2023 Dec 5;10(1):868.
80. Giaccherini M, Gori L, Gentiluomo M, Farinella R, Cervenka K, Skieceviciene J, et al. A scan of all coding region variants of the human genome, identifies 13q12.2-rs9579139 and 15q24.1-rs2277598 as novel risk loci for pancreatic ductal adenocarcinoma. *Carcinogenesis*. 2023 Dec 2;44(8–9):642–9.
81. Waldmann A, Borchers P, Katalinic A. Temporal trends in age- and stage-specific incidence of colorectal adenocarcinomas in Germany. *BMC Cancer*. 2023 Dec 1;23(1):1180.
82. Wolf S, Augustin M, Hagenström K, Garbe C, Baltus H, Eisemann N, et al. Evaluation of skin cancer screening in Germany - Spatiotemporal associations between skin cancer screening and skin cancer mortality based on ambulatory claims data. *J Dtsch Dermatol Ges*. 2023 Dec;21 Suppl 5:22–31.
83. Wang A, Shen J, Rodriguez AA, Saunders EJ, Chen F, Janivara R, et al. Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants. *Nat Genet*. 2023 Dec;55(12):2065–74.
84. Schumann L, Eisemann N, Augustin J, Kieschke J, Meyer M, Kajüter H, et al. Association of early-stage incidence and mortality in malignant melanoma - a population-based ecological study. *J Dtsch Dermatol Ges*. 2023 Dec;21 Suppl 5:33–40.
85. Schneider J, Hernandez D, Schlender M, Arndt V. Out-of-pocket payments and loss of income among long-term breast cancer survivors in Germany: a multi-regional population-based study. *J Cancer Surviv*. 2023 Dec;17(6):1639–59.
86. Hübner J, Baltus H, Eisemann N, Rohr M, Schumann L, Augustin J, et al. Evaluation of early skin cancer detection in Germany with cancer registry data - challenges, solutions and current trends. *J Dtsch Dermatol Ges*. 2023 Dec;21 Suppl 5:13–20.
87. Heidenreich A, Fuchshofen R, Elsner S, Gieseler F, Katalinic A, Hübner J. Contributing and limiting factors to guideline-adherent therapy in senior and elderly breast cancer patients: a

questionnaire-based cross-sectional study using clinical and cancer registry data in Germany. *J Cancer Res Clin Oncol*. 2023 Dec;149(19):17297–306.

88. Garbe C, Augustin M, Augustin J, Baltus H, Eisemann N, Hübner J, et al. Evaluation of skin cancer screening in Germany - participation, tumor detection and interval tumors based on SHI data. *J Dtsch Dermatol Ges*. 2023 Dec;21 Suppl 5:3–11.
89. Aleshchenko E, Apfelbacher C, Baust K, Calaminus G, Droege P, Glogner J, et al. VersKiK: Study protocol of an observational registry-based study on the current state of follow-up care and adherence to follow-up guidelines after cancer in childhood or adolescence. *Cancer Epidemiol*. 2023 Dec;87:102469.
90. Jakob D, Schmoor C, Reuten R, Frevert ML, Dannehl D, Jansen L, et al. Characteristics, Treatment Patterns and Survival of International Federation of Gynecology and Obstetrics Stage IV Epithelial Ovarian Cancer-A Population-Based Study. *Cancers (Basel)*. 2023 Nov 30;15(23).
91. de Beijer IAE, Hardijzer EC, Haupt R, Grabow D, Balaguer J, Bardi E, et al. Barriers and facilitators to the implementation of a new European eHealth solution (SurPass v2.0): the PanCareSurPass Open Space study. *J Cancer Surviv*. 2023 Nov 28;
92. Levi H, Carmi S, Rosset S, Yerushalmi R, Zick A, Yablonski-Peretz T, et al. Evaluation of European-based polygenic risk score for breast cancer in Ashkenazi Jewish women in Israel. *J Med Genet*. 2023 Nov 27;60(12):1186–97.
93. Yang K, Doege D, Thong MSY, Koch-Gallenkamp L, Weisser L, Bertram H, et al. Diabetes mellitus in long-term survivors with colorectal, breast, or prostate cancer: Prevalence and prognosis. A population-based study. *Cancer*. 2023 Nov 23;
94. Schliemann A, Teroerde A, Beurer B, Hammersen F, Fischer D, Katalinic A, et al. Reduced Psychosocial Well-Being among the Children of Women with Early-Onset Breast Cancer. *Curr Oncol*. 2023 Nov 21;30(12):10057–74.
95. Jansen L, Schwettmann L, Behr C, Eberle A, Holleczeck B, Justenhoven C, et al. Trends in cancer incidence by socioeconomic deprivation in Germany in 2007 to 2018: An ecological registry-based study. *Int J Cancer*. 2023 Nov 15;153(10):1784–96.
96. Gali K, Orban E, Ozga AK, Möhl A, Behrens S, Holleczeck B, et al. Does breast cancer modify the long-term relationship between lifestyle behaviors and mortality? A prospective analysis of breast cancer survivors and population-based controls. *Cancer*. 2023 Nov 11;
97. Schraw JM, Petridou ET, Bonaventure A, Dockerty JD, Karalexi M, Ntzani E, et al. Breastfeeding and risk of childhood brain tumors: a report from the Childhood Cancer and Leukemia International Consortium. *Cancer Causes Control*. 2023 Nov;34(11):1005–15.
98. Leiter U, Heppt MV, Steeb T, Alter M, Amaral T, Bauer A, et al. S3 guideline ‘actinic keratosis and cutaneous squamous cell carcinoma’ - update 2023, part 2: epidemiology and

etiology, diagnostics, surgical and systemic treatment of cutaneous squamous cell carcinoma (cSCC), surveillance and prevention. *J Dtsch Dermatol Ges.* 2023 Nov;21(11):1422–33.

99. De Santis KK, Helmer S, Barnes B, Kraywinkel K, Imhoff M, Müller-Eberstein R, et al. Impact of the COVID-19 pandemic on oncological care in Germany: rapid review. *J Cancer Res Clin Oncol.* 2023 Nov;149(15):14329–40.
100. Braulke F, Kober K, Rieken S, Brand T, Hartz T, Seipke S, et al. Adherence to interdisciplinary tumor board recommendations as an expression of quality-assured patient care: results of a bicentric German analysis. *J Cancer Res Clin Oncol.* 2023 Nov;149(16):14775–84.
101. Crispin-Rios Y, Faura-Gonzales M, Torres-Roman JS, Quispe-Vicuña C, Franco-Jimenez US, Valcarcel B, et al. Testicular cancer mortality in Latin America and the Caribbean: trend analysis from 1997 to 2019. *BMC Cancer.* 2023 Oct 27;23(1):1038.
102. Hintschich CA, Gerken M, Spoerl S, Bohr C, Künzel J. Primary Diagnoses of Squamous Cell Carcinoma of the Head and Neck During the COVID-19 Pandemic. *Dtsch Arztebl Int.* 2023 Oct 20;120(42):719–20.
103. Tetzlaff F, Nowossadeck E, Jansen L, Michalski N, Barnes B, Kraywinkel K, et al. Widening area-based socioeconomic inequalities in cancer mortality in Germany between 2003 and 2019. *Sci Rep.* 2023 Oct 19;13(1):17833.
104. Göbel S, Wingerter A, Prochaska JH, Schulz A, Neu MA, Henninger N, et al. Development and Phenotype of Heart Failure in Long-Term Survivors of Childhood Cancer: The CVSS Study. *J Am Heart Assoc.* 2023 Oct 3;12(19):e030020.
105. Thomas M, Su YR, Rosenthal EA, Sakoda LC, Schmit SL, Timofeeva MN, et al. Combining Asian and European genome-wide association studies of colorectal cancer improves risk prediction across racial and ethnic populations. *Nat Commun.* 2023 Oct 2;14(1):6147.
106. Schütte W, Gütz S, Nehls W, Blum TG, Brückl W, Buttmann-Schweiger N, et al. [Prevention, Diagnosis, Therapy, and Follow-up of Lung Cancer - Interdisciplinary Guideline of the German Respiratory Society and the German Cancer Society - Abridged Version]. *Pneumologie.* 2023 Oct;77(10):671–813.
107. Heywang-Köbrunner SH, Hacker A, Jänsch A, Hertlein M, Mieskes C, Elsner S, et al. Use of novel artificial intelligence computer-assisted detection (AI-CAD) for screening mammography: an analysis of 17,884 consecutive two-view full-field digital mammography screening exams. *Acta Radiol.* 2023 Oct;64(10):2697–703.
108. Heppt MV, Leiter U, Steeb T, Alter M, Amaral T, Bauer A, et al. S3 guideline ‘actinic keratosis and cutaneous squamous cell carcinoma’ - update 2023, part 1: treatment of actinic keratosis, actinic cheilitis, cutaneous squamous cell carcinoma in situ (Bowen’s disease),

- occupational disease and structures of care. *J Dtsch Dermatol Ges.* 2023 Oct;21(10):1249–62.
109. Hatzipanagiotou ME, Pigerl M, Gerken M, Rappke S, Zeltner V, Hetterich M, et al. Does timing of neoadjuvant chemotherapy influence the prognosis in patients with early triple negative breast cancer? *J Cancer Res Clin Oncol.* 2023 Oct;149(13):11941–50.
 110. Grundmann N, Voigtländer S, Hakimhashemi A, Pape UF, Meyer M, Müller-Nordhorn J. Site-specific trends in gastroenteropancreatic neuroendocrine neoplasms in Bavaria, Germany. *Cancer Med.* 2023 Oct;12(19):19949–58.
 111. Fischl A, Gerken M, Roos P, Haedenkamp T, Hillberg A, Klinkhammer-Schalke M, et al. Does the distance to the cancer center affect psycho-oncological care and emergency visits of patients with IDH wild-type gliomas? A retrospective study. *Neurooncol Pract.* 2023 Oct;10(5):446–53.
 112. Galetzka W, Kowall B, Jusi C, Huessler EM, Stang A. Distance-Metric Learning for Personalized Survival Analysis. *Entropy (Basel).* 2023 Sept 30;25(10).
 113. Schmitt J, Klinkhammer-Schalke M, Bierbaum V, Gerken M, Bobeth C, Rößler M, et al. Initial Cancer Treatment in Certified Versus Non-Certified Hospitals. *Dtsch Arztebl Int.* 2023 Sept 29;120(39):647–54.
 114. Strebel S, Baust K, Grabow D, Byrne J, Langer T, Am Zehnhoff-Dinnesen A, et al. Auditory complications among childhood cancer survivors and health-related quality of life: a PanCareLIFE study. *J Cancer Surviv.* 2023 Sept 22;
 115. Völkel V, Gerken M, Kleihues-van Tol K, Schoffer O, Bierbaum V, Bobeth C, et al. Treatment of Colorectal Cancer in Certified Centers: Results of a Large German Registry Study Focusing on Long-Term Survival. *Cancers (Basel).* 2023 Sept 15;15(18).
 116. Ziegler J, Gruendner J, Rosenau L, Erpenbeck M, Prokosch HU, Deppenwiese N. Towards a Bavarian Oncology Real World Data Research Platform. *Stud Health Technol Inform.* 2023 Sept 12;307:78–85.
 117. Rudolph C, Engholm G, Pritzkeleit R, Storm HH, Katalinic A. Colorectal Cancer Survival in German-Danish Border Regions-A Registry-Based Cohort Study. *Cancers (Basel).* 2023 Sept 8;15(18).
 118. Matz M, Valkov M, Šekerija M, Luttman S, Caldarella A, Coleman MP, et al. Worldwide trends in esophageal cancer survival, by sub-site, morphology, and sex: an analysis of 696,974 adults diagnosed in 60 countries during 2000-2014 (CONCORD-3). *Cancer Commun (Lond).* 2023 Sept;43(9):963–80.
 119. Lodde GC, Hassel J, Wulfken LM, Meier F, Mohr P, Kähler K, et al. Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) study. *Eur J Cancer.* 2023

Sept;191:112957.

120. Liu Z, Thong MSY, Doege D, Koch-Gallenkamp L, Weisser L, Bertram H, et al. Benefit finding, posttraumatic growth and health-related quality of life in long-term cancer survivors: a prospective population-based study. *Acta Oncol.* 2023 Sept;62(9):1124–31.
121. Abdalla TSA, Klinkhammer-Schalke M, Zeissig SR, Tol KK van, Honselmann KC, Braun R, et al. Prognostic factors after resection of locally advanced non-functional pancreatic neuroendocrine neoplasm: an analysis from the German Cancer Registry Group of the Society of German Tumor Centers. *J Cancer Res Clin Oncol.* 2023 Sept;149(11):8535–43.
122. Wellbrock M, Spix C, Ronckers CM, Grabow D, Filbert AL, Borkhardt A, et al. Temporal patterns of childhood cancer survival 1991 to 2016: A nationwide register-study based on data from the German Childhood Cancer Registry. *Int J Cancer.* 2023 Aug 15;153(4):742–55.
123. Carus J, Trübe L, Szczepanski P, Nürnberg S, Hees H, Bartels S, et al. Mapping the Oncological Basis Dataset to the Standardized Vocabularies of a Common Data Model: A Feasibility Study. *Cancers (Basel).* 2023 Aug 11;15(16).
124. Middha P, Wang X, Behrens S, Bolla MK, Wang Q, Dennis J, et al. A genome-wide gene-environment interaction study of breast cancer risk for women of European ancestry. *Breast Cancer Res.* 2023 Aug 9;25(1):93.
125. Katalinic A, Halber M, Meyer M, Pflüger M, Eberle A, Nennecke A, et al. Population-Based Clinical Cancer Registration in Germany. *Cancers (Basel).* 2023 Aug 2;15(15).
126. Voigtländer S, Hakimhashemi A, Grundmann N, Radespiel-Tröger M, Inwald EC, Ortmann O, et al. Impact of the COVID-19 pandemic on reported cancer diagnoses in Bavaria, Germany. *J Cancer Res Clin Oncol.* 2023 Aug;149(10):7493–503.
127. van Leeuwen M, Kieffer JM, Young TE, Annunziata MA, Arndt V, Arraras JJ, et al. Phase III study of the European Organisation for Research and Treatment of Cancer Quality of Life cancer survivorship core questionnaire. *J Cancer Surviv.* 2023 Aug;17(4):1111–30.
128. Dimou N, Kim AE, Flanagan O, Murphy N, Diez-Obrero V, Shcherbina A, et al. Probing the diabetes and colorectal cancer relationship using gene - environment interaction analyses. *Br J Cancer.* 2023 Aug;129(3):511–20.
129. Bhardwaj M, Schöttker B, Holleczer B, Brenner H. Enhanced selection of people for lung cancer screening using AHRH (cg05575921) or F2RL3 (cg03636183) methylation as biological markers of smoking exposure. *Cancer Commun (Lond).* 2023 Aug;43(8):956–9.
130. Abdalla TSA, Pieper L, Kist M, Thomaschewski M, Klinkhammer-Schalke M, Zeissig SR, et al. Gastrointestinal stromal tumors of the upper GI tract: population-based analysis of epidemiology, treatment and outcome based on data from the German Clinical Cancer Registry Group. *J Cancer Res Clin Oncol.* 2023 Aug;149(10):7461–9.

131. Möhl A, Behrens S, Flaßkamp F, Obi N, Kreienbrinck A, Holleczeck B, et al. The impact of cardiovascular disease on all-cause and cancer mortality: results from a 16-year follow-up of a German breast cancer case-control study. *Breast Cancer Res.* 2023 July 27;25(1):89.
132. Reulen RC, Winter DL, Diallo I, Veres C, Llanas D, Allodji RS, et al. Risk Factors for Primary Bone Cancer After Childhood Cancer: A PanCare Childhood and Adolescent Cancer Survivor Care and Follow-Up Studies Nested Case-Control Study. *J Clin Oncol.* 2023 July 20;41(21):3735–46.
133. Morawitz J, Bruckmann NM, Jannusch K, Dietzel F, Milosevic A, Bittner AK, et al. Conventional Imaging, MRI and (18)F-FDG PET/MRI for N and M Staging in Patients with Newly Diagnosed Breast Cancer. *Cancers (Basel).* 2023 July 17;15(14).
134. Ernst M, Hinz A, Brähler E, Merzenich H, Faber J, Wild PS, et al. Quality of life after pediatric cancer: comparison of long-term childhood cancer survivors' quality of life with a representative general population sample and associations with physical health and risk indicators. *Health Qual Life Outcomes.* 2023 July 4;21(1):65.
135. Teufel A, Meindl-Beinker NM, Hösel P, Gerken M, Roig A, Ebert MP, et al. Characteristics and outcome of patients with small bowel adenocarcinoma (SBA). *J Cancer Res Clin Oncol.* 2023 July;149(8):4579–90.
136. Scharl S, Sprötge T, Gerken M, Scharl A, Ortmann O, Kölbl O, et al. Guideline concordant therapy improves survival in high-grade endometrial cancer patients. *J Cancer Res Clin Oncol.* 2023 July;149(8):4761–9.
137. Nachtsheim L, Mayer M, Meyer MF, Oesterling F, Kajueter H, Arolt C, et al. Incidence and clinical outcome of primary carcinomas of the major salivary glands: 10-year data from a population-based state cancer registry in Germany. *J Cancer Res Clin Oncol.* 2023 July;149(7):3811–21.
138. Klinkhammer-Schalke M, Wesselmann S, Bruns J, Nettekoven G, Tillack A, Follmann M, et al. [Further Development and Interoperability in Oncological Care Structures, Quality Control and Research]. *Gesundheitswesen.* 2023 July;85(7):649–56.
139. Teufel A, Rodriguez I, Winzler C, Kokh D, Ebert MP, Surovtsova I, et al. Clinical Characterization of HCC/CCA Mixed Cancers in a Population-based Cohort. *J Gastrointest Liver Dis.* 2023 June 22;32(2):190–6.
140. Heidenreich A, Elsner S, Wörler F, Hübner J, Schües C, Rehmann-Sutter C, et al. Physicians' perspectives on family caregivers' roles in elderly cancer patients' therapies: a qualitative, interview-based study. *Support Care Cancer.* 2023 June 9;31(7):387.
141. Spix C, Erdmann F, Grabow D, Ronckers C. Childhood and adolescent cancer in Germany - an overview. *J Health Monit.* 2023 June;8(2):79–94.
142. Kraywinkel K, Flegar L, Huber J, Groeben C. [Cancer registries in Germany: what does the

- future hold for urology?]. *Aktuelle Urol.* 2023 June;54(3):208–12.
143. Hess T, Maj C, Gehlen J, Borisov O, Haas SL, Gockel I, et al. Dissecting the genetic heterogeneity of gastric cancer. *EBioMedicine.* 2023 June;92:104616.
 144. Campa D, Gentiluomo M, Stein A, Aoki MN, Oliverius M, Vodičková L, et al. The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer. *Crit Rev Oncol Hematol.* 2023 June;186:104020.
 145. Rensing M, Becker C, Müller C, Mahmoudpour SH, Calaminus G, Langer T, et al. Equivalent doses for anticancer agents used in pediatric oncology: A literature review and evaluation of a novel approach for conversion factors. *Cancer Rep (Hoboken).* 2023 May;6(5):e1811.
 146. Fernández-Pacheco M, Gerken M, Ortmann O, Ignatov A, Klinkhammer-Schalke M, Hatzipanagiotou ME, et al. Impact of cavity shaving on residual tumor rates in patients with primary invasive carcinoma and carcinoma in situ in breast conserving surgery. *Arch Gynecol Obstet.* 2023 May;307(5):1573–83.
 147. Möller L, Wellmann I, Stang A, Kajüter H. The Epidemiology of Colorectal Cancer in Younger and Older Patients. *Dtsch Arztebl Int.* 2023 Apr 21;120(16):277–83.
 148. Eisfeld C, Kajüter H, Möller L, Wellmann I, Shumilov E, Stang A. Time trends in survival and causes of death in multiple myeloma: a population-based study from Germany. *BMC Cancer.* 2023 Apr 6;23(1):317.
 149. Schmitt J, Bierbaum T, Geraedts M, Gothe H, Härter M, Hoffmann F, et al. [Not Available]. *Gesundheitswesen.* 2023 Apr;85(4):215–22.
 150. Neis F, Holleczeck B, Henes M, Juhasz-Böss I, Wallwiener D, Neis KJ. Proposal for a descriptive and differentiated presentation of the longitudinal impact of the new organized cancer screening guideline and HPV vaccination in Germany. *Arch Gynecol Obstet.* 2023 Apr;307(4):1125–36.
 151. Machens A, Lorenz K, Huessler EM, Stang A, Weber F, Dralle H. Temporal trends in referrals of RET gene carriers for neck surgery to a tertiary surgical center in the era of international management guidelines. *Endocrine.* 2023 Apr;80(1):100–10.
 152. Lang LM, Behr C, Ludwig M, Walker J, Christian Lange H, Basedow F, et al. Routine practice data of three cancer entities: Comparison among cancer registry and health insurance data. *Z Evid Fortbild Qual Gesundhwes.* 2023 Apr;177:65–72.
 153. Keim U, Katalinic A, Holleczeck B, Wakkee M, Garbe C, Leiter U. Incidence, mortality and trends of cutaneous squamous cell carcinoma in Germany, the Netherlands, and Scotland. *Eur J Cancer.* 2023 Apr;183:60–8.

154. Hammersen F, Fischer D, Pursche T, Strobel AM, Katalinic A, Labohm L, et al. Young Adult German Breast Cancer Patients Participating in a Three-Week Inpatient Mother-Child Rehab Program Have High Needs for Supportive Care. *Cancers (Basel)*. 2023 Mar 15;15(6).
155. Thong MSY, Doege D, Weißer L, Koch-Gallenkamp L, Jansen L, Bertram H, et al. Persisting Deficits in Health-Related Quality of Life of Colorectal Cancer Survivors 14-24 Years Post-Diagnosis: A Population-Based Study. *Curr Oncol*. 2023 Mar 14;30(3):3373–90.
156. Girardi F, Matz M, Stiller C, You H, Marcos Gragera R, Valkov MY, et al. Global survival trends for brain tumors, by histology: analysis of individual records for 556,237 adults diagnosed in 59 countries during 2000-2014 (CONCORD-3). *Neuro Oncol*. 2023 Mar 14;25(3):580–92.
157. Girardi F, Di Carlo V, Stiller C, Gatta G, Woods RR, Visser O, et al. Global survival trends for brain tumors, by histology: Analysis of individual records for 67,776 children diagnosed in 61 countries during 2000-2014 (CONCORD-3). *Neuro Oncol*. 2023 Mar 14;25(3):593–606.
158. Carreras-Torres R, Kim AE, Lin Y, Díez-Obrero V, Bien SA, Qu C, et al. Genome-wide Interaction Study with Smoking for Colorectal Cancer Risk Identifies Novel Genetic Loci Related to Tumor Suppression, Inflammation, and Immune Response. *Cancer Epidemiol Biomarkers Prev*. 2023 Mar 6;32(3):315–28.
159. Russo A, Blettner M, Merzenich H, Wollschlaeger D, Erdmann F, Gianicolo E. Incidence of childhood leukemia before and after shut down of nuclear power plants in Germany in 2011: A population-based register study during 2004 to 2019. *Int J Cancer*. 2023 Mar 1;152(5):913–20.
160. Reinwald F, Justenhoven C. Impact of the COVID-19 pandemic on number and stages of tumors - data of a German cancer registry. *Acta Oncol*. 2023 Mar;62(3):315–7.
161. Meyer S, Buser L, Haferkamp S, Berneburg M, Maisch T, Klinkhammer-Schalke M, et al. Identification of high-risk patients with a seven-biomarker prognostic signature for adjuvant treatment trial recruitment in American Joint Committee on Cancer v8 stage I-IIA cutaneous melanoma. *Eur J Cancer*. 2023 Mar;182:77–86.
162. Girschik C, Muchalla P, Kowall B, Zwanziger D, Erbel R, Ittermann T, et al. [Regional Differences in Thyroid Function Parameters: A Comparison of European Cohort Studies]. *Gesundheitswesen*. 2023 Mar;85(3):175–80.
163. Fernandez-Rozadilla C, Timofeeva M, Chen Z, Law P, Thomas M, Schmit S, et al. Author Correction: Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries. *Nat Genet*. 2023 Mar;55(3):519–20.
164. Dubrall D, Sachs B, Kraywinkel K, Schulz M, Schmid M, Fischer-Barth W, et al. Analyses of Basal and Squamous Cell Carcinoma Reported as an Adverse Drug Reaction and

Comparison with Cases from the Cancer Registry from Germany. *Drugs R D*. 2023 Mar;23(1):21–33.

165. Bobeth C, Tol KK van, Rößler M, Bierbaum V, Gerken M, Günster C, et al. [Methodology and Attribution Success of a Data Linkage of Clinical Registry Data with Health Insurance Data]. *Gesundheitswesen*. 2023 Mar;85(S 02):S154–61.
166. van den Oever SR, de Beijer IAE, Kremer LCM, Alfes M, Balaguer J, Bardi E, et al. Barriers and facilitators to implementation of the interoperable Survivorship Passport (SurPass) v2.0 in 6 European countries: a PanCareSurPass online survey study. *J Cancer Surviv*. 2023 Feb 20;
167. Völkel V, Steinger B, Koller M, Klinkhammer-Schalke M, Lindberg-Scharf P. Colorectal cancer survivors' long-term recollections of their illness and therapy up to seven years after enrolment into a randomised controlled clinical trial. *BMC Cancer*. 2023 Feb 13;23(1):149.
168. Dudley IM, Sunguc C, Heymer EJ, Winter DL, Teepe JC, Belle FN, et al. Risk of subsequent primary lymphoma in a cohort of 69,460 five-year survivors of childhood and adolescent cancer in Europe: The PanCareSurFup study. *Cancer*. 2023 Feb 1;129(3):426–40.
169. Zahnreich S, Yusifli K, Poplawski A, Eckhard LS, Mirsch J, Hankeln T, et al. Replication stress drives chromosomal instability in fibroblasts of childhood cancer survivors with second primary neoplasms. *DNA Repair (Amst)*. 2023 Feb;122:103435.
170. Morawitz J, Sigl B, Rubbert C, Bruckmann NM, Dietzel F, Häberle LJ, et al. Clinical Decision Support for Axillary Lymph Node Staging in Newly Diagnosed Breast Cancer Patients Based on (18)F-FDG PET/MRI and Machine Learning. *J Nucl Med*. 2023 Feb;64(2):304–11.
171. Arndt V, Doege D, Fröhling S, Albers P, Algül H, Bargou R, et al. Cancer care in German centers of excellence during the first 2 years of the COVID-19 pandemic. *J Cancer Res Clin Oncol*. 2023 Feb;149(2):913–9.
172. Spoerl S, Gerken M, Fischer R, Spoerl S, Kirschneck C, Wolf S, et al. Statin Use Ameliorates Survival in Oral Squamous Cell Carcinoma-Data from a Population-Based Cohort Study Applying Propensity Score Matching. *Biomedicines*. 2023 Jan 27;11(2).
173. Mueller SH, Lai AG, Valkovskaya M, Michailidou K, Bolla MK, Wang Q, et al. Aggregation tests identify new gene associations with breast cancer in populations with diverse ancestry. *Genome Med*. 2023 Jan 26;15(1):7.
174. Spoerl S, Erber R, Gerken M, Taxis J, Ludwig N, Nieberle F, et al. A20 as a Potential New Tool in Predicting Recurrence and Patient's Survival in Oral Squamous Cell Carcinoma. *Cancers (Basel)*. 2023 Jan 21;15(3).
175. Schuldt K, Trocchi P, Stang A. Skin Cancer Screening and Medical Treatment Intensity in

Patients with Malignant Melanoma and Non-Melanocytic Skin Cancer. *Dtsch Arztebl Int*. 2023 Jan 20;120(3):33–9.

176. Thomas M, Su YR, Rosenthal EA, Sakoda LC, Schmit SL, Timofeeva MN, et al. Combining Asian-European Genome-Wide Association Studies of Colorectal Cancer Improves Risk Prediction Across Race and Ethnicity. *medRxiv : the preprint server for health sciences*. United States; 2023. p. 2023.01.19.23284737.
177. Acs M, Gerken M, Schmitt V, Piso P, Königsrainer A, Baransi S, et al. Role of HIPEC after Complete Cytoreductive Surgery (CRS) in Peritoneal Recurrence of Platinum-Sensitive Recurrent Ovarian Cancer (OC): The Aim for Standardization at Two Reference Centers for CRS. *Cancers (Basel)*. 2023 Jan 7;15(2).
178. de Baat EC, Feijen EAM, Reulen RC, Allodji RS, Bagnasco F, Bardi E, et al. Risk Factors for Heart Failure Among Pan-European Childhood Cancer Survivors: A PanCareSurFup and ProCardio Cohort and Nested Case-Control Study. *J Clin Oncol*. 2023 Jan 1;41(1):96–106.
179. Sunguc C, Hawkins MM, Winter DL, Dudley IM, Heymer EJ, Teeppen JC, et al. Risk of subsequent primary oral cancer in a cohort of 69,460 5-year survivors of childhood and adolescent cancer in Europe: the PanCareSurFup study. *Br J Cancer*. 2023 Jan;128(1):80–90.
180. Stocker H, Beyer L, Perna L, Rujescu D, Holleczech B, Beyreuther K, et al. Association of plasma biomarkers, p-tau181, glial fibrillary acidic protein, and neurofilament light, with intermediate and long-term clinical Alzheimer's disease risk: Results from a prospective cohort followed over 17 years. *Alzheimers Dement*. 2023 Jan;19(1):25–35.
181. Stang A, Trocchi P, Kajüter H, Trabert B, Oosterhuis JW, McGlynn KA. Age-incidence patterns of seminoma and nonseminoma among males and females in Germany and the United States, 2008-2016. *Andrology*. 2023 Jan;11(1):65–72.
182. Herout R, Baunacke M, Flegar L, Borkowetz A, Reicherz A, Koch R, et al. Upper tract urothelial carcinoma in Germany: epidemiological data and surgical treatment trends in a total population analysis from 2006 to 2019. *World J Urol*. 2023 Jan;41(1):127–33.
183. Fernandez-Rozadilla C, Timofeeva M, Chen Z, Law P, Thomas M, Schmit S, et al. Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries. *Nat Genet*. 2023 Jan;55(1):89–99.
184. Zeissig SR, Emrich K, Reinwald F, Kasper B, Kleihues-van Tole K, Justenhoven C, et al. Sarcoma Research with Cancer Registry Data: Data and Peculiarities of Germany in the Light of Other Countries. *Oncol Res Treat*. 2023;46(9):370–81.
185. Struck JP, Ozimek T, Schnoor M, Offermann A, Guenther M, Roesch MC, et al. The Role of Urine and Washing Cytology in Primary Transurethral Resection of Bladder Tumours. *Urol Int*. 2023;107(8):792–800.

186. Konermann FM, Gessler N, Wohlmuth P, Behr J, Feldhege J, Gloeckner C, et al. High In-Hospital Mortality in SARS-CoV-2-Infected Patients with Active Cancer Disease during Omicron Phase of the Pandemic: Insights from the CORONA Germany Study. *Oncol Res Treat.* 2023;46(5):201–10.
187. Grandt CL, Brackmann LK, Poplawski A, Schwarz H, Marini F, Hankeln T, et al. Identification of lncRNAs involved in response to ionizing radiation in fibroblasts of long-term survivors of childhood cancer and cancer-free controls. *Front Oncol.* 2023;13:1158176.
188. Giusti F, Martos C, Trama A, Bettio M, Sanvisens A, Audisio R, et al. Cancer treatment data available in European cancer registries: Where are we and where are we going? *Front Oncol.* 2023;13:1109978.
189. Dieckmann KP, Isbarn H, Trocchi P, Kießling M, Wülfing C, Stang A. No evidence for seasonal variations of the incidence of testicular germ cell tumours in Germany. *PLoS One.* 2023;18(5):e0286309.
190. Demuru E, Rossi S, Ventura L, Dal Maso L, Guzzinati S, Katalinic A, et al. Estimating complete cancer prevalence in Europe: validity of alternative vs standard completeness indexes. *Front Oncol.* 2023;13:1114701.
191. Dahm S, Barnes B, Kraywinkel K. Detection of missed deaths in cancer registry data to reduce bias in long-term survival estimation. *Front Oncol.* 2023;13:1088657.
192. Brackmann LK, Foraita R, Schwarz H, Poplawski A, Hankeln T, Galetzka D, et al. Self-administered questionnaire assessing childhood cancer treatments and associated risks for adverse health outcomes - The KiKme study. *Front Oncol.* 2023;13:1150629.
193. Fochler S, Weitmann K, Domin M, Hoffmann W. Reasons for Non-Attendance in the German National Mammography Screening Program: Which Barriers Can Be Overcome Using Telephone Counseling?-A Randomized Controlled Trial. *Healthcare (Basel).* 2022 Dec 21;11(1).
194. Jung AY, Ahearn TU, Behrens S, Middha P, Bolla MK, Wang Q, et al. Distinct Reproductive Risk Profiles for Intrinsic-Like Breast Cancer Subtypes: Pooled Analysis of Population-Based Studies. *J Natl Cancer Inst.* 2022 Dec 8;114(12):1706–19.
195. Trocchi P, Mach P, Kimmig KR, Stang A. Ovarian cancer surgery in Germany: An analysis of the nationwide hospital file 2005-2015. *Womens Health (Lond).* 2022 Dec;18:17455065221075903.
196. Trama A, Bernasconi A, Botta L, Byrne J, Grabow D, Reulen RC, et al. Late mortality reduction among survivors of germ cell tumors in childhood and adolescence in Europe: A report from the PanCareSurFup cohort. *Pediatr Blood Cancer.* 2022 Dec;69(12):e29991.
197. Teufel A, Li M, Gerken M, Ebert MP, Schlitt HJ, Evert M, et al. Second Cancer After Additive Chemotherapy in Patients With Colon Cancer. *Clin Colorectal Cancer.* 2022

Dec;21(4):354–61.

198. Mor JM, Rokohl AC, Dahm S, Kraywinkel K, Heindl LM. Epidemiology of uveal melanomas in Germany. *Acta Ophthalmol*. 2022 Dec;100(8):e1774–5.
199. Kollhorst B, Reinders T, Grill S, Eberle A, Intemann T, Kieschke J, et al. Record linkage of claims and cancer registries data-Evaluation of a deterministic linkage approach based on indirect personal identifiers. *Pharmacoepidemiol Drug Saf*. 2022 Dec;31(12):1287–93.
200. Forster F, Herrera R, Hoopmann M, Kieschke J, Deitermann B, Radon K. Residential proximity to oil and gas production sites and hematologic malignancies: A case-control study. *Am J Ind Med*. 2022 Dec;65(12):985–93.
201. Doege D, Thong MSY, Koch-Gallenkamp L, Bertram H, Eberle A, Holleczeck B, et al. Clinical and sociodemographic determinants of disease-specific health-related quality of life in long-term breast cancer survivors. *J Cancer Res Clin Oncol*. 2022 Dec;148(12):3461–73.
202. Cabasag CJ, Vignat J, Ferlay J, Arndt V, Lemmens V, Praagman J, et al. The preventability of cancer in Europe: A quantitative assessment of avoidable cancer cases across 17 cancer sites and 38 countries in 2020. *Eur J Cancer*. 2022 Dec;177:15–24.
203. Brenner H, Cardoso R, Heisser T, Hoffmeister M, Holleczeck B. Indications of substantial delay of colorectal cancer diagnoses due to COVID-19 in Germany. *Lancet Reg Health Eur*. 2022 Dec;23:100543.
204. Botta L, Gatta G, Capocaccia R, Stiller C, Cañete A, Dal Maso L, et al. Long-term survival and cure fraction estimates for childhood cancer in Europe (EUROCare-6): results from a population-based study. *Lancet Oncol*. 2022 Dec;23(12):1525–36.
205. Borkhardt A, Schüz J, Trübenbach C, Wellbrock M, Spix C, Erdmann F. Temporal changes of the incidence of childhood B-cell precursor acute lymphoblastic leukaemia in Germany during the COVID-19 pandemic. *Leukemia*. 2022 Dec;36(12):2908–11.
206. Bhardwaj M, Schöttker B, Holleczeck B, Brenner H. Comparison of discrimination performance of 11 lung cancer risk models for predicting lung cancer in a prospective cohort of screening-age adults from Germany followed over 17 years. *Lung Cancer*. 2022 Dec;174:83–90.
207. Kist M, Thomaschewski M, Keck Y, Abdalla TSA, Zeissig SR, Kleihues-van Tol K, et al. Specifics of Young Gastric Cancer Patients: A Population-Based Analysis of 46,110 Patients with Gastric Cancer from the German Clinical Cancer Registry Group. *Cancers (Basel)*. 2022 Nov 30;14(23).
208. Gaziano L, Sun L, Arnold M, Bell S, Cho K, Kaptoge SK, et al. Mild-to-Moderate Kidney Dysfunction and Cardiovascular Disease: Observational and Mendelian Randomization Analyses. *Circulation*. 2022 Nov 15;146(20):1507–17.

209. Yu H, Raut JR, Bhardwaj M, Zhang Y, Sandner E, Schöttker B, et al. A serum microRNA signature for enhanced selection of people for lung cancer screening. *Cancer Commun (Lond)*. 2022 Nov;42(11):1222–5.
210. Stürzl R, Gerken M, Bruns C, Klinkhammer-Schalke M, Pauer A, Piso P. [Surgical treatment of adenocarcinoma of the esophagogastric junction type II : Comparison between transhiatal extended gastrectomy and thoracoabdominal esophagectomy]. *Chirurgie (Heidelb)*. 2022 Nov;93(11):1072–81.
211. Scherer-Trame S, Jansen L, Koch-Gallenkamp L, Arndt V, Chang-Claude J, Hoffmeister M, et al. Quality of life, distress, and posttraumatic growth 5 years after colorectal cancer diagnosis according to history of inpatient rehabilitation. *J Cancer Res Clin Oncol*. 2022 Nov;148(11):3015–28.
212. Li X, Schöttker B, Holleczer B, Brenner H. Association of longitudinal repeated measurements of frailty index with mortality: Cohort study among community-dwelling older adults. *EClinicalMedicine*. 2022 Nov;53:101630.
213. Eyl-Armbruster RE, Thong MSY, Carr PR, Jansen L, Chang-Claude J, Hoffmeister M, et al. Change Toward Healthier Lifestyles Is Associated With Better Health-Related Quality of Life in Long-Term Colorectal Cancer Survivors. *J Natl Compr Canc Netw*. 2022 Nov;20(11):1233-1243.e10.
214. Acs M, Gerken M, Gajic I, Mayr M, Zustin J, Piso P. Ten-year single-center experience with treatment of primary diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). *Langenbecks Arch Surg*. 2022 Nov;407(7):3057–67.
215. Shan L, Zhang L, Zhu X, Wang Z, Fang S, Lin J, et al. Chinese never smokers with adenocarcinoma of the lung are younger and have fewer lymph node metastases than smokers. *Respir Res*. 2022 Oct 29;23(1):293.
216. Justenhoven C, Rieger B. The Impact of the Corona Pandemic on Reported Data Relating to Cancer Diagnoses, Therapy, and Follow-Up. *Dtsch Arztebl Int*. 2022 Oct 21;119(42):724–5.
217. Schmidt ME, Goldschmidt S, Hermann S, Steindorf K. Late effects, long-term problems and unmet needs of cancer survivors. *Int J Cancer*. 2022 Oct 15;151(8):1280–90.
218. Peters A, Peters A, Greiser KH, Göttlicher S, Ahrens W, Albrecht M, et al. Framework and baseline examination of the German National Cohort (NAKO). *Eur J Epidemiol*. 2022 Oct;37(10):1107–24.
219. Nikšić M, Matz M, Valkov M, Marcos-Gragera R, Stiller C, Rosso S, et al. World-wide trends in net survival from pancreatic cancer by morphological sub-type: An analysis of 1,258,329 adults diagnosed in 58 countries during 2000-2014 (CONCORD-3). *Cancer Epidemiol*. 2022 Oct;80:102196.

220. Dixon-Suen SC, Lewis SJ, Martin RM, English DR, Boyle T, Giles GG, et al. Physical activity, sedentary time and breast cancer risk: a Mendelian randomisation study. *Br J Sports Med.* 2022 Oct;56(20):1157–70.
221. Kendzia B, Kaerlev L, Ahrens W, Merletti F, Eriksson M, Guénel P, et al. Lifetime Exposure to Welding Fumes and Risk of Some Rare Cancers. *Am J Epidemiol.* 2022 Sept 28;191(10):1753–65.
222. Armbrust R, Ledwon P, Von Rüsten A, Schneider C, Sehouli J. Primary Treatment Results in Patients with Ovarian, Fallopian or Peritoneal Cancer-Results of a Clinical Cancer Registry Database Analysis in Germany. *Cancers (Basel).* 2022 Sept 24;14(19).
223. Bundred JR, Michael S, Stuart B, Cutress RI, Beckmann K, Holleczeck B, et al. Margin status and survival outcomes after breast cancer conservation surgery: prospectively registered systematic review and meta-analysis. *BMJ.* 2022 Sept 21;378:e070346.
224. Aleshchenko E, Swart E, Spix C, Voigt M, Trocchi P, Langer T, et al. Long-term care, care needs and wellbeing of individuals after cancer in childhood or adolescence (VersKiK): study protocol of a large scale multi-methods non-interventional study. *BMC Health Serv Res.* 2022 Sept 20;22(1):1176.
225. Gambichler T, Stang A, Mansour R, Scheel CH, Nick C, Abu Rached N, et al. Prognostic Potential of the Baseline Pan-Immune-Inflammation Value and Neutrophil/Lymphocyte Ratio in Stage I to III Melanoma Patients. *Cancers (Basel).* 2022 Sept 11;14(18).
226. Li X, Delerue T, Schöttker B, Holleczeck B, Grill E, Peters A, et al. Derivation and validation of an epigenetic frailty risk score in population-based cohorts of older adults. *Nat Commun.* 2022 Sept 7;13(1):5269.
227. Grandt CL, Brackmann LK, Poplawski A, Schwarz H, Hummel-Bartenschlager W, Hankeln T, et al. Radiation-response in primary fibroblasts of long-term survivors of childhood cancer with and without second primary neoplasms: the KiKme study. *Mol Med.* 2022 Sept 6;28(1):105.
228. Zhu A, Kuznia S, Niedermaier T, Holleczeck B, Schöttker B, Brenner H. Vitamin D-binding protein, total, ‘nonbioavailable,’ bioavailable, and free 25-hydroxyvitamin D, and mortality in a large population-based cohort of older adults. *J Intern Med.* 2022 Sept;292(3):463–76.
229. Stang A, Schuldt K, Trocchi P, Neusser S, Speckemeier C, Pahmeier K, et al. The impossibility of mortality evaluation of skin cancer screening in Germany based on health insurance data: a case-control study. *Eur J Cancer.* 2022 Sept;173:52–8.
230. Oesterling F, Kajüter H, Nachtsheim L, Löning T, Stang A. Letter: Parotid gland metastases of cutaneous squamous cell carcinoma - a corroboration at population level. *Head Neck Pathol.* 2022 Sept;16(3):836–7.
231. Gorski M, Rasheed H, Teumer A, Thomas LF, Graham SE, Sveinbjornsson G, et al. Genetic

- loci and prioritization of genes for kidney function decline derived from a meta-analysis of 62 longitudinal genome-wide association studies. *Kidney Int.* 2022 Sept;102(3):624–39.
232. Di Carlo V, Stiller CA, Eisemann N, Bordoni A, Matz M, Curado MP, et al. Does the morphology of cutaneous melanoma help to explain the international differences in survival? Results from 1578482 adults diagnosed during 2000-2014 in 59 countries (CONCORD-3). *Br J Dermatol.* 2022 Sept;187(3):364–80.
 233. Abele M, Voggel S, Bremensdorfer C, Spix C, Erdmann F, Kuhlen M, et al. Incidences and characteristics of primary lung malignancies in childhood in Germany: An analysis of population-based data from German cancer registries. *Pediatr Blood Cancer.* 2022 Sept;69(9):e29744.
 234. Tanoey J, Baechle C, Brenner H, Deckert A, Fricke J, Günther K, et al. Birth Order, Caesarean Section, or Daycare Attendance in Relation to Child- and Adult-Onset Type 1 Diabetes: Results from the German National Cohort. *Int J Environ Res Public Health.* 2022 Aug 31;19(17).
 235. Köngeter A, Schickhardt C, Jungkunz M, Bergbold S, Mehlis K, Winkler EC. Patients' Willingness to Provide Their Clinical Data for Research Purposes and Acceptance of Different Consent Models: Findings From a Representative Survey of Patients With Cancer. *J Med Internet Res.* 2022 Aug 25;24(8):e37665.
 236. Eichberger J, Weber F, Spanier G, Gerken M, Schreml S, Schulz D, et al. Loss of MMP-27 Predicts Mandibular Bone Invasion in Oral Squamous Cell Carcinoma. *Cancers (Basel).* 2022 Aug 22;14(16).
 237. Braun R, Klinkhammer-Schalke M, Zeissig SR, Kleihus van Tol K, Bolm L, Honselmann KC, et al. Clinical Outcome and Prognostic Factors of Pancreatic Adenosquamous Carcinoma Compared to Ductal Adenocarcinoma-Results from the German Cancer Registry Group. *Cancers (Basel).* 2022 Aug 16;14(16).
 238. Zhu A, Kuznia S, Niedermaier T, Holleczeck B, Schöttker B, Brenner H. Consistent Inverse Associations of Total, 'Bioavailable', Free, and 'Non-Bioavailable' Vitamin D with Incidence of Diabetes among Older Adults with Lower Baseline HbA(1c) ($\leq 6\%$) Levels. *Nutrients.* 2022 Aug 11;14(16).
 239. Tian Y, Kim AE, Bien SA, Lin Y, Qu C, Harrison TA, et al. Genome-Wide Interaction Analysis of Genetic Variants With Menopausal Hormone Therapy for Colorectal Cancer Risk. *J Natl Cancer Inst.* 2022 Aug 8;114(8):1135–48.
 240. Wellbrock M, Zeeb H, Spix C, Grabow D, Borkhardt A, Erdmann F. Survival in Children Below the Age of 15 Years With Leukemia: Temporal Patterns in Eastern and Western Germany Since German Reunification. *Hemasphere.* 2022 Aug;6(8):e755.
 241. Stang A, Wellmann I, Holleczeck B, Fell B, Turner S, Lutz MP, et al. Incidence and relative survival of pancreatic adenocarcinoma and pancreatic neuroendocrine neoplasms in

- Germany, 2009-2018. An in-depth analysis of two population-based cancer registries. *Cancer Epidemiol.* 2022 Aug;79:102204.
242. Schirmacher R, Rieger B, Justenhoven C. [Treatment in Certified Centres (DKG): Decision Factors of Lung Cancer Patients]. *Pneumologie.* 2022 Aug;76(8):547–51.
 243. Mantke R, Schneider C, Weylandt K, Gretschel S, Marusch F, Kube R, et al. [Epidemiology and surgical treatment of pancreatic cancer in the State of Brandenburg : Analysis of 5418 cases]. *Chirurgie (Heidelb).* 2022 Aug;93(8):788–801.
 244. Hartlapp I, Valta-Seufzer D, Siveke JT, Algül H, Goekkurt E, Siegler G, et al. Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113). *ESMO Open.* 2022 Aug;7(4):100552.
 245. Liang LA, Zeissig SR, Schaubberger G, Merzweiler S, Radde K, Fischbeck S, et al. Colposcopy non-attendance following an abnormal cervical cancer screening result: a prospective population-based cohort study. *BMC Womens Health.* 2022 July 9;22(1):285.
 246. Schüz J, Borkhardt A, Bouaoun L, Erdmann F. The impact of the COVID-19 pandemic on the future incidence of acute lymphoblastic leukaemia in children: Projections for Germany under a COVID-19 related scenario. *Int J Cancer.* 2022 July 1;151(1):153–5.
 247. Gao X, Huang N, Jiang M, Holleczeck B, Schöttker B, Huang T, et al. Mortality and morbidity risk prediction for older former smokers based on a score of smoking history: evidence from UK Biobank and ESTHER cohorts. *Age Ageing.* 2022 July 1;51(7):afac154.
 248. Nguyen TNM, Sha S, Chen LJ, Holleczeck B, Brenner H, Schöttker B. Strongly increased risk of gastric and duodenal ulcers among new users of low-dose aspirin: results from two large cohorts with new-user design. *Aliment Pharmacol Ther.* 2022 July;56(2):251–62.
 249. Li X, Schöttker B, Holleczeck B, Brenner H. Associations of DNA methylation algorithms of aging and cancer risk: Results from a prospective cohort study. *EBioMedicine.* 2022 July;81:104083.
 250. Gennari P, Tchaikovski S, Mészáros J, Gerken M, Klinkhammer-Schalke M, Toth G, et al. Protective effect of pre-operative conization in patients undergoing surgical treatment for early-stage cervical cancer. *Gynecol Oncol.* 2022 July;166(1):57–60.
 251. Flegar L, Kraywinkel K, Zacharis A, Aksoy C, Koch R, Eisenmenger N, et al. Treatment trends for muscle-invasive bladder cancer in Germany from 2006 to 2019. *World J Urol.* 2022 July;40(7):1715–21.
 252. Camargo MC, Song M, Xu X, Zhao I, Sampson JN, Etemadi A, et al. Urinary estrogen metabolites and gastric cancer risk among postmenopausal women. *Cancer Rep (Hoboken).* 2022 July;5(7):e1574.

253. Betzmann D, Döring M, Blumenstock G, Erdmann F, Grabow D, Lang P, et al. Impact of Serum Insulin-Like Growth Factor 1 on Hematopoietic Stem Cell Transplantation Outcome in Pediatric Cancer Patients. *Transplant Cell Ther.* 2022 July;28(7):355.e1-355.e9.
254. Achajew A, Brecht IB, Radespiel-Tröger M, Meyer M, Metzler M, Bremensdorfer C, et al. Rare pediatric tumors in Germany - not as rare as expected: a study based on data from the Bavarian Cancer Registry and the German Childhood Cancer Registry. *Eur J Pediatr.* 2022 July;181(7):2723–30.
255. Speckemeier C, Pahmeier K, Trocchi P, Schuldt K, Lax H, Nonnemacher M, et al. One-year follow-up healthcare costs of patients diagnosed with skin cancer in Germany: a claims data analysis. *BMC Health Serv Res.* 2022 June 11;22(1):771.
256. Roessler M, Schmitt J, Bobeth C, Gerken M, Kleihues-van Tol K, Reissfelder C, et al. Is treatment in certified cancer centers related to better survival in patients with pancreatic cancer? Evidence from a large German cohort study. *BMC Cancer.* 2022 June 7;22(1):621.
257. Stang A, Schmidt B. Reporting of Statistical Inference in Abstracts of Major Cancer Journals, 1990 to 2020. *JAMA Netw Open.* 2022 June 1;5(6):e2218337.
258. Möllers T, Stocker H, Perna L, Rujescu D, Holleczeck B, Schöttker B, et al. Subjective short-term memory difficulties at ages 50-75 predict dementia risk in a community-based cohort followed over 17 years. *Age Ageing.* 2022 June 1;51(6):afac113.
259. Voigtländer S, Hakimhashemi A, Grundmann N, Meyer M, Müller-Nordhorn J. Comparison of trends in early-onset colorectal cancer in North America and Europe. *Lancet Gastroenterol Hepatol.* 2022 June;7(6):505–6.
260. Spoerl S, Gerken M, Chamilos C, Spoerl S, Fischer R, Vielsmeier V, et al. Clinical significance of panendoscopy in initial staging of oral squamous cell carcinoma and detection of synchronous second malignancies of the upper aerodigestive tract - Insights from a retrospective population-based cohort study. *J Craniomaxillofac Surg.* 2022 June;50(6):515–22.
261. Sachs B, Dubrall D, Kraywinkel K, Schulz M, Schmid M, Bate J, et al. Descriptive analysis of 179 German reports of melanoma reported to an adverse drug reaction database as a drug-related adverse effect, and comparison with melanoma cases contained in German cancer registries. *Clin Exp Dermatol.* 2022 June;47(6):1078–87.
262. Filippini Velázquez G, Schiele S, Gerken M, Neumaier S, Hackl C, Mayr P, et al. Predictive preoperative clinical score for patients with liver-only oligometastatic colorectal cancer. *ESMO Open.* 2022 June;7(3):100470.
263. Erdmann F, Spix C, Schrappe M, Borkhardt A, Schüz J. Temporal changes of the incidence of childhood cancer in Germany during the COVID-19 pandemic: Updated analyses from the German Childhood Cancer Registry. *Lancet Reg Health Eur.* 2022 June;17:100398.

264. Nguyen TNM, Chen LJ, Trares K, Stocker H, Holleczeck B, Beyreuther K, et al. Long-term low-dose acetylsalicylic use shows protective potential for the development of both vascular dementia and Alzheimer's disease in patients with coronary heart disease but not in other individuals from the general population: results from two large cohort studies. *Alzheimers Res Ther.* 2022 May 28;14(1):75.
265. Chronaki C, Charalambous E, Cangilioli G, Schreier G, van den Oever S, van der Pal H, et al. Factors Influencing Implementation of the Survivorship Passport: The IT Perspective. *Stud Health Technol Inform.* 2022 May 16;293:161–8.
266. Jordahl KM, Shcherbina A, Kim AE, Su YR, Lin Y, Wang J, et al. Beyond GWAS of Colorectal Cancer: Evidence of Interaction with Alcohol Consumption and Putative Causal Variant for the 10q24.2 Region. *Cancer Epidemiol Biomarkers Prev.* 2022 May 4;31(5):1077–89.
267. Kube SJ, Blattmann C, Bielack SS, Kager L, Kaatsch P, Kühne T, et al. Secondary malignant neoplasms after bone and soft tissue sarcomas in children, adolescents, and young adults. *Cancer.* 2022 May 1;128(9):1787–800.
268. Pigeot I, Bongaerts B, Eberle A, Katalinic A, Kieschke J, Luttmann S, et al. [Linkage of claims data with data from epidemiological cancer registries: possibilities and limitations in the German federal states]. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz.* 2022 May;65(5):615–23.
269. Hippert F, Desing L, Diez S, Witowski A, Bernbeck B, Abele M, et al. Rare Tumors in Children and Adolescents - the STEP Working Group's Evolution to a Prospective Registry. *Klin Padiatr.* 2022 May;234(3):146–53.
270. Bhardwaj M, Schöttker B, Holleczeck B, Benner A, Schrotz-King P, Brenner H. Potential of Inflammatory Protein Signatures for Enhanced Selection of People for Lung Cancer Screening. *Cancers (Basel).* 2022 Apr 26;14(9).
271. Spoerl S, Spoerl S, Reil S, Gerken M, Ludwig N, Taxis J, et al. Prognostic Value of Perineural Invasion on Survival and Recurrence in Oral Squamous Cell Carcinoma. *Diagnostics (Basel).* 2022 Apr 24;12(5).
272. Yang K, Liu Z, Thong MSY, Doege D, Arndt V. Higher Incidence of Diabetes in Cancer Patients Compared to Cancer-Free Population Controls: A Systematic Review and Meta-Analysis. *Cancers (Basel).* 2022 Apr 2;14(7).
273. Wang X, Chen H, Middha Kapoor P, Su YR, Bolla MK, Dennis J, et al. A genome-wide gene-based gene-environment interaction study of breast cancer in more than 90,000 women. *Cancer Res Commun.* 2022 Apr;2(4):211–9.
274. Schmutzler RK, Schmitz-Luhn B, Borisch B, Devilee P, Eccles D, Hall P, et al. Risk-Adjusted Cancer Screening and Prevention (RiskAP): Complementing Screening for Early Disease Detection by a Learning Screening Based on Risk Factors. *Breast Care (Basel).*

2022 Apr;17(2):208–23.

275. Kuss O, Becher H, Wienke A, Ittermann T, Ostrzinski S, Schipf S, et al. Statistical Analysis in the German National Cohort (NAKO) - Specific Aspects and General Recommendations. *Eur J Epidemiol*. 2022 Apr;37(4):429–36.
276. Kaatsch P, Trübenbach C, Kaiser M, Erdmann F, Spix C, Grabow D. [The 41,000 long-term survivor cohort of the German Childhood Cancer Registry]. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz*. 2022 Apr;65(4):453–61.
277. Deichmann S, Dworschak O, Kulemann B, Höppner J, Bolm L, Klinkhammer-Schalke M, et al. [Incidence, Treatment and Survival in Pancreatic Cancer- Data of the Nationwide Oncological Quality Conference from a Surgical Perspective]. *Zentralbl Chir*. 2022 Apr;147(2):147–54.
278. Markeeva-Ilisevic E, Holleczech B, Becher H, Winkler V. Non-melanoma skin cancer among ethnic German immigrants (resettler) from the former Soviet Union: a cohort study from 1990 to 2007. *Arch Public Health*. 2022 Mar 18;80(1):85.
279. Thong MSY, van Noorden CJF, Steindorf K, Arndt V. Correction to: Cancer-Related Fatigue: Causes and Current Treatment Options. *Curr Treat Options Oncol*. 2022 Mar;23(3):450–1.
280. Sahm M, Schneider C, Gretschel S, Kube R, Becker A, Günther M, et al. [Reality of care of colorectal cancer in the State of Brandenburg : With special consideration of the number of hospital cases and certification as a colorectal cancer center]. *Chirurg*. 2022 Mar;93(3):274–85.
281. Eberl M, Tanaka LF, Kraywinkel K, Klug SJ. Incidence of Smoking-Related Second Primary Cancers After Lung Cancer in Germany: An Analysis of Nationwide Cancer Registry Data. *J Thorac Oncol*. 2022 Mar;17(3):388–98.
282. Clausen S, Falk M, Oesterling F, Fehr A, Stang A, Boecker W, et al. Outcome of Ordinary Polymorphous Adenocarcinomas of the Salivary Glands in Comparison With Papillary and Cribriform Subtypes. *Anticancer Res*. 2022 Mar;42(3):1455–63.
283. Röhrmoser K, Ignatov A, Gerken M, Ortmann O, Klinkhammer-Schalke M, Papathemelis T. Risk factors and temporal patterns of recurrences in patients with vulvar cancer: implications for follow-up intervals and duration. *J Cancer Res Clin Oncol*. 2022 Feb 18;
284. Zolk O, von dem Knesebeck A, Graf N, Simon T, Hero B, Abdul-Khaliq H, et al. Cardiovascular Health Status And Genetic Risk In Survivors of Childhood Neuroblastoma and Nephroblastoma Treated With Doxorubicin: Protocol of the Pharmacogenetic Part of the LESS-Anthra Cross-Sectional Cohort Study. *JMIR Res Protoc*. 2022 Feb 17;11(2):e27898.
285. Bolm L, Zemskov S, Zeller M, Baba T, Roldan J, Harrison JM, et al. Concepts and

Outcomes of Perioperative Therapy in Stage IA-III Pancreatic Cancer-A Cross-Validation of the National Cancer Database (NCDB) and the German Cancer Registry Group of the Society of German Tumor Centers (GCRG/ADT). *Cancers (Basel)*. 2022 Feb 9;14(4).

286. Byrne J, Schmidtmann I, Rashid H, Hagberg O, Bagnasco F, Bardi E, et al. Impact of era of diagnosis on cause-specific late mortality among 77 423 five-year European survivors of childhood and adolescent cancer: The PanCareSurFup consortium. *Int J Cancer*. 2022 Feb 1;150(3):406–19.
287. Völkel V, Schatz S, Draeger T, Gerken M, Klinkhammer-Schalke M, Fürst A. Transanal total mesorectal excision: short- and long-term results of the first hundred cases of a certified colorectal cancer center in Germany. *Surg Endosc*. 2022 Feb;36(2):1172–80.
288. Struck JP, Schnoor M, Schulze A, Hupe MC, Ozimek T, Oppolzer IA, et al. Impact of COVID-19 crisis on medical care of patients with metastasized uro-oncologic disease under systemic cancer therapy: a multicenter study in German university hospitals. *World J Urol*. 2022 Feb;40(2):409–18.
289. Acs M, Halmy L, Isgandarova S, Blaj S, Gerken M, Hormann B, et al. Hyperthermic Intraperitoneal Chemotherapy With Cisplatin and Doxorubicin for 90 Minutes Versus 60 Minutes After Cytoreductive Surgery (CRS). Does the 30-Minute Difference Matter? A Comparative Study in a High Volume Centre. *Anticancer Res*. 2022 Feb;42(2):1019–29.
290. Stang A. Cancer Mortality in Hamburg (Germany) 1872-2019. *Dtsch Arztebl Int*. 2022 Jan 28;119(4):41–6.
291. Dennis J, Tyrer JP, Walker LC, Michailidou K, Dorling L, Bolla MK, et al. Rare germline copy number variants (CNVs) and breast cancer risk. *Commun Biol*. 2022 Jan 18;5(1):65.
292. Onyije FM, Olsson A, Baaken D, Erdmann F, Stanulla M, Wollschläger D, et al. Environmental Risk Factors for Childhood Acute Lymphoblastic Leukemia: An Umbrella Review. *Cancers (Basel)*. 2022 Jan 13;14(2).
293. Juhnke BO, Gessi M, Gerber NU, Friedrich C, Mynarek M, von Bueren AO, et al. Treatment of embryonal tumors with multilayered rosettes with carboplatin/etoposide induction and high-dose chemotherapy within the prospective P-HIT trial. *Neuro Oncol*. 2022 Jan 5;24(1):127–37.
294. Merzenich H, Baaken D, Schneider A, Neu MA, Wingerter A, Faber J, et al. Mortality risk among 5-year survivors of childhood cancer in Germany-Results from the CVSS study (Cardiac and Vascular late Sequelae in long-term Survivors of childhood cancer study). *Int J Cancer*. 2022 Jan 1;150(1):67–72.
295. Dutzmann CM, Spix C, Popp I, Kaiser M, Erdmann F, Erlacher M, et al. Cancer in Children With Fanconi Anemia and Ataxia-Telangiectasia-A Nationwide Register-Based Cohort Study in Germany. *J Clin Oncol*. 2022 Jan 1;40(1):32–9.

296. Vehling S, Mehnert-Theuerkauf A, Philipp R, Härter M, Kraywinkel K, Kuhnert R, et al. Prevalence of mental disorders in patients with cancer compared to matched controls - secondary analysis of two nationally representative surveys. *Acta Oncol.* 2022 Jan;61(1):7–13.
297. Thong MSY, Doege D, Weißer L, Koch-Gallenkamp L, Bertram H, Eberle A, et al. Health and life insurance-related problems in very long-term cancer survivors in Germany: a population-based study. *J Cancer Res Clin Oncol.* 2022 Jan;148(1):155–62.
298. Scharl S, Sprötge T, Gerken M, Scharl A, Ignatov A, Inwald EC, et al. Factors influencing treatment decision and guideline conformity in high-grade endometrial cancer patients: a population-based study. *Arch Gynecol Obstet.* 2022 Jan;305(1):203–13.
299. Voigtländer S, Hakimhashemi A, Grundmann N, Rees F, Meyer M, Algül H, et al. Trends of colorectal cancer incidence according to age, anatomic site, and histological subgroup in Bavaria: A registry-based study. *Front Oncol.* 2022;12:904546.
300. Vener C, Rossi S, Minicozzi P, Marcos-Gragera R, Poirel HA, Maynadié M, et al. Clear Improvement in Real-World Chronic Myeloid Leukemia Survival: A Comparison With Randomized Controlled Trials. *Front Oncol.* 2022;12:892684.
301. Sternjakob-Marthaler A, Berkó-Göttel B, Rissland J, Schöpe J, Taurian E, Müller H, et al. Human papillomavirus vaccination of girls in the German model region Saarland: Insurance data-based analysis and identification of starting points for improving vaccination rates. *PLoS One.* 2022;17(9):e0273332.
302. Schleicher O, Horndasch A, Krumbholz M, Sembill S, Bremensdorfer C, Grabow D, et al. Patient-reported long-term outcome following allogeneic hematopoietic stem cell transplantation in pediatric chronic myeloid leukemia. *Front Oncol.* 2022;12:963223.
303. Schleicher O, Horndasch A, Krumbholz M, Sembill S, Bremensdorfer C, Grabow D, et al. Corrigendum: Patient-reported long-term outcome following allogeneic hematopoietic stem cell transplantation in pediatric chronic myeloid leukemia. *Front Oncol.* 2022;12:1116757.
304. Pokora RM, Büttner M, Schulz A, Schuster AK, Merzenich H, Teifke A, et al. Determinants of mammography screening participation-a cross-sectional analysis of the German population-based Gutenberg Health Study (GHS). *PLoS One.* 2022;17(10):e0275525.
305. Lohse S, Sternjakob-Marthaler A, Lagemann P, Schöpe J, Rissland J, Seiwert N, et al. German federal-state-wide seroprevalence study of 1(st) SARS-CoV-2 pandemic wave shows importance of long-term antibody test performance. *Commun Med (Lond).* 2022;2:52.
306. Galetzka D, Böck J, Wagner L, Dittrich M, Sinizyn O, Ludwig M, et al. Hypermethylation of RAD9A intron 2 in childhood cancer patients, leukemia and tumor cell lines suggest a role for oncogenic transformation. *EXCLI J.* 2022;21:117–43.

307. Gaisser A, Eckford RD, Arndt V, Doege D, Kludt E, Ubels J, et al. [Nearly two years of the coronavirus pandemic from the perspective of people affected by cancer]. *Onkologe (Berl)*. 2022;28(3):248–52.
308. Fante MA, Felsenstein M, Mayer S, Gerken M, Klinkhammer-Schalke M, Herr W, et al. All-Oral Low-Dose Chemotherapy TEPIP is Effective and Well-Tolerated in Relapsed/Refractory Patients With Aggressive B-Cell Lymphoma. *Front Oncol*. 2022;12:852987.
309. Ernst M, Brähler E, Faber J, Wild PS, Merzenich H, Beutel ME. A Mixed-Methods Investigation of Medical Follow-Up in Long-Term Childhood Cancer Survivors: What Are the Reasons for Non-Attendance? *Front Psychol*. 2022;13:846671.
310. Brackmann LK, Foraita R, Schwarz H, Galetzka D, Zahnreich S, Hankeln T, et al. Late health effects and changes in lifestyle factors after cancer in childhood with and without subsequent second primary cancers - the KiKme case-control study. *Front Oncol*. 2022;12:1037276.
311. Petrova E, Wellner J, Nording AK, Braun R, Honselmann KC, Bolm L, et al. Survival Outcome and Prognostic Factors for Pancreatic Acinar Cell Carcinoma: Retrospective Analysis from the German Cancer Registry Group. *Cancers (Basel)*. 2021 Dec 4;13(23).
312. Lindberg-Scharf P, Steinger B, Koller M, Hofstädter A, Ortmann O, Kurz J, et al. Long-term improvement of quality of life in patients with breast cancer: supporting patient-physician communication by an electronic tool for inpatient and outpatient care. *Support Care Cancer*. 2021 Dec;29(12):7865–75.
313. Keim U, Gandini S, Amaral T, Katalinic A, Holleczeck B, Flatz L, et al. Cutaneous melanoma attributable to UVR exposure in Denmark and Germany. *Eur J Cancer*. 2021 Dec;159:98–104.
314. Hübner J, Mattutat J, Katalinic A. [Years of life lost: known methods and a refined approach using the example of the most frequent causes of death in Germany]. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz*. 2021 Nov;64(11):1463–72.
315. Spoerl S, Spanier G, Reiter E, Gerken M, Haferkamp S, Grosse J, et al. Head and neck melanoma: outcome and predictors in a population-based cohort study. *Head Face Med*. 2021 Oct 22;17(1):45.
316. Völkel V, Klinkhammer-Schalke M, Fürst A. Falling Mortality Thanks to Improved Treatment for Colorectal Cancer. *Dtsch Arztebl Int*. 2021 Oct 1;118(39):664.
317. Voigtländer S, Hakimhashemi A, Inwald EC, Ortmann O, Gerken M, Klug SJ, et al. The Impact of the COVID-19 Pandemic on Cancer Incidence and Treatment by Cancer Stage in Bavaria, Germany. *Dtsch Arztebl Int*. 2021 Oct 1;118(39):660–1.

318. Liu Z, Doege D, Thong MSY, Koch-Gallenkamp L, Bertram H, Eberle A, et al. Distress mediates the relationship between cognitive appraisal of medical care and benefit finding/posttraumatic growth in long-term cancer survivors. *Cancer*. 2021 Oct 1;127(19):3680–90.
319. Girardi F, Rous B, Stiller CA, Gatta G, Fersht N, Storm HH, et al. The histology of brain tumors for 67 331 children and 671 085 adults diagnosed in 60 countries during 2000-2014: a global, population-based study (CONCORD-3). *Neuro Oncol*. 2021 Oct 1;23(10):1765–76.
320. Rudolph CES, Engholm G, Pritzkeleit R, Storm HH, Katalinic A. Survival of breast cancer patients in German-Danish border regions - A registry-based cohort study. *Cancer Epidemiol*. 2021 Oct;74:102001.
321. Deppenwiese N, Delpy P, Lambarki M, Lablans M. ADT2FHIR - A Tool for Converting ADT/GEKID Oncology Data to HL7 FHIR Resources. *Stud Health Technol Inform*. 2021 Sept 21;283:104–10.
322. Scharl S, Becher C, Gerken M, Scharl A, Anapolski M, Ignatov A, et al. Is there a benefit for adjuvant radio(chemo)therapy in early cervical cancer? Results from a population-based study. *Arch Gynecol Obstet*. 2021 Sept;304(3):759–71.
323. Liu Z, Thong MSY, Doege D, Koch-Gallenkamp L, Bertram H, Eberle A, et al. Prevalence of benefit finding and posttraumatic growth in long-term cancer survivors: results from a multi-regional population-based survey in Germany. *Br J Cancer*. 2021 Sept;125(6):877–83.
324. Waldmann A, Hübner J, Katalinic A. Trends Over Time in Breast-Cancer-Specific Mortality in Germany. *Dtsch Arztebl Int*. 2021 Aug 9;118(31–32):538–9.
325. Finke I, Behrens G, Maier W, Schwettmann L, Pritzkeleit R, Holleccek B, et al. Small-area analysis on socioeconomic inequalities in cancer survival for 25 cancer sites in Germany. *Int J Cancer*. 2021 Aug 1;149(3):561–72.
326. Gennari P, Gerken M, Mészáros J, Klinkhammer-Schalke M, Ortmann O, Eggemann H, et al. Minimal-invasive or open approach for surgery of early cervical cancer: the treatment center matters. *Arch Gynecol Obstet*. 2021 Aug;304(2):503–10.
327. Scharl S, Gerken M, Sprötge T, Kronberger K, Scharl A, Ignatov A, et al. Comparison of survival outcomes and effects of therapy between subtypes of high-grade endometrial cancer - a population-based study. *Acta Oncol*. 2021 July;60(7):897–903.
328. Garbe C, Keim U, Gandini S, Amaral T, Katalinic A, Holleccek B, et al. Epidemiology of cutaneous melanoma and keratinocyte cancer in white populations 1943-2036. *Eur J Cancer*. 2021 July;152:18–25.
329. Cardoso R, Guo F, Heisser T, Hackl M, Ihle P, De Schutter H, et al. Colorectal cancer incidence, mortality, and stage distribution in European countries in the colorectal cancer

- screening era: an international population-based study. *Lancet Oncol.* 2021 July;22(7):1002–13.
330. Sacchetto L, Rosso S, Comber H, Bouchardy C, Broganelli P, Galceran J, et al. Skin melanoma deaths within 1 or 3 years from diagnosis in Europe. *Int J Cancer.* 2021 June 15;148(12):2898–905.
 331. Doege D, Thong MSY, Weißer L, Koch-Gallenkamp L, Jansen L, Bertram H, et al. Health-Related Quality of Life in Very Long-Term Cancer Survivors 14-24 Years Post-Diagnosis Compared to Population Controls: A Population-Based Study. *Cancers (Basel).* 2021 June 1;13(11).
 332. Windschüttl S, Pukrop T, Herrmann A, Lindberg-Scharf P, Heudobler D, Herr W, et al. [Development of a screening workflow to identify patient needs in an interdisciplinary oncological day clinic]. *Z Evid Fortbild Qual Gesundheitswes.* 2021 June;163:30–7.
 333. Staubach P, Scharl A, Ignatov A, Ortmann O, Inwald EC, Hildebrandt T, et al. Sentinel lymph node detection by means of indocyanine green using the Karl Storz VITOM(®) fluorescence camera: a comparison between primary sentinel lymph node biopsy versus sentinel lymph node biopsy after neoadjuvant chemotherapy. *J Cancer Res Clin Oncol.* 2021 June;147(6):1813–23.
 334. Hetterich M, Gerken M, Ortmann O, Inwald EC, Klinkhammer-Schalke M, Eggemann H, et al. Adjuvant chemotherapy for breast cancer patients with axillary lymph node micrometastases. *Breast Cancer Res Treat.* 2021 June;187(3):715–27.
 335. Gieseler F, Heidenreich A, Schubert J, Frielitz F, Rehmann-Sutter C, Wörler F, et al. The role of family confidants and caregivers in the care of older cancer patients: Extending the concept of ‘shared decision-making’. *Health Sci Rep.* 2021 June;4(2):e281.
 336. Scheel K, Franke T, Weikert A, Dick M, Walter A, Zeidler J, et al. Record Linkage in Clinical Cancer Registration: Experiences and Findings from Lower Saxony. *Stud Health Technol Inform.* 2021 May 24;278:101–9.
 337. Jansen L, Erb C, Nennecke A, Finke I, Pritzkeleit R, Holleczeck B, et al. Socioeconomic deprivation and cancer survival in a metropolitan area: An analysis of cancer registry data from Hamburg, Germany. *Lancet Reg Health Eur.* 2021 May;4:100063.
 338. Bouvier AM, Jooste V, Sanchez-Perez MJ, Bento MJ, Rocha Rodrigues J, Marcos-Gragera R, et al. Differences in the management and survival of metastatic colorectal cancer in Europe. A population-based study. *Dig Liver Dis.* 2021 May;53(5):639–45.
 339. Markowiak T, Dakkak B, Loch E, Großer C, Klinkhammer-Schalke M, Hofmann HS, et al. Video-assisted pulmonary metastectomy is equivalent to thoracotomy regarding resection status and survival. *J Cardiothorac Surg.* 2021 Apr 15;16(1):84.
 340. Spoerl S, Gerken M, Mamilos A, Fischer R, Wolf S, Nieberle F, et al. Lymph node ratio as

a predictor for outcome in oral squamous cell carcinoma: a multicenter population-based cohort study. *Clin Oral Investig*. 2021 Apr;25(4):1705–13.

341. Schmidt ME, Bergbold S, Hermann S, Steindorf K. Knowledge, perceptions, and management of cancer-related fatigue: the patients' perspective. *Support Care Cancer*. 2021 Apr;29(4):2063–71.
342. Pruessmann J, Pursche T, Hammersen F, Katalinic A, Fischer D, Waldmann A. Conditional Disease-Free and Overall Survival of 1,858 Young Women with Non-Metastatic Breast Cancer and with Participation in a Post-Therapeutic Rehab Programme according to Clinical Subtypes. *Breast Care (Basel)*. 2021 Apr;16(2):163–72.
343. Elsner SA, Salek SS, Finlay AY, Hagemeyer A, Bottomley CJ, Katalinic A, et al. Validation of the German version of the Family Reported Outcome Measure (FROM-16) to assess the impact of disease on the partner or family member. *Health Qual Life Outcomes*. 2021 Mar 24;19(1):106.
344. González Maldonado S, Motsch E, Trotter A, Kauczor HU, Heussel CP, Hermann S, et al. Overdiagnosis in lung cancer screening: Estimates from the German Lung Cancer Screening Intervention Trial. *Int J Cancer*. 2021 Mar 1;148(5):1097–105.
345. Markowiak T, Neu R, Ansari MKA, Großer C, Klinkhammer-Schalke M, Hofmann HS, et al. Surgical Cytoreduction and HITOC for Thymic Malignancies with Pleural Dissemination. *Thorac Cardiovasc Surg*. 2021 Mar;69(2):157–64.
346. Krensel M, Petersen J, Stephan B, Katalinic A, Augustin J. Comparison of patient pathways in the early detection of skin cancer - a claims data analysis. *J Dtsch Dermatol Ges*. 2021 Mar;19(3):389–98.
347. Hammersen F, Pursche T, Fischer D, Katalinic A, Waldmann A. Psychosocial and family-centered support among breast cancer patients with dependent children. *Psychooncology*. 2021 Mar;30(3):361–8.
348. Spanier G, Ugele I, Nieberle F, Symeou L, Schmidhofer S, Brand A, et al. The predictive power of CD3(+) T cell infiltration of oral squamous cell tumors is limited to non-diabetic patients. *Cancer Lett*. 2021 Feb 28;499:209–19.
349. Jansen L, Kanbach J, Finke I, Arndt V, Emrich K, Holleczeck B, et al. Estimation of the Potentially Avoidable Excess Deaths Associated with Socioeconomic Inequalities in Cancer Survival in Germany. *Cancers (Basel)*. 2021 Jan 19;13(2).
350. Lillini R, Tittarelli A, Bertoldi M, Ritchie D, Katalinic A, Pritzkeleit R, et al. Water and Soil Pollution: Ecological Environmental Study Methodologies Useful for Public Health Projects. A Literature Review. *Rev Environ Contam Toxicol*. 2021;256:179–214.
351. Eckford RD, Gaisser A, Arndt V, Baumann M, Kludt E, Mehlis K, et al. The COVID-19 Pandemic and Cancer Patients in Germany: Impact on Treatment, Follow-Up Care and

Psychological Burden. *Front Public Health*. 2021;9:788598.

352. Spoerl S, Gerken M, Fischer R, Mamilos A, Spoerl S, Wolf S, et al. Lymphatic and vascular invasion in oral squamous cell carcinoma: Implications for recurrence and survival in a population-based cohort study. *Oral Oncol*. 2020 Dec;111:105009.
353. Robold T, Neumeier J, Ried M, Neu R, Sziklavari Z, Grosser C, et al. [Surgical Treatment of Lung Cancer: How Has the Introduction of the 8th Edition of the TNM Classification Affected Guideline-Based Therapy?]. *Zentralbl Chir*. 2020 Dec;145(6):589–96.
354. Schmidt ME, Hermann S, Arndt V, Steindorf K. Prevalence and severity of long-term physical, emotional, and cognitive fatigue across 15 different cancer entities. *Cancer Med*. 2020 Nov;9(21):8053–61.
355. Doege D, Thong MSY, Koch-Gallenkamp L, Jansen L, Bertram H, Eberle A, et al. Age-specific prevalence and determinants of depression in long-term breast cancer survivors compared to female population controls. *Cancer Med*. 2020 Nov;9(22):8713–21.
356. Sirri E, Kieschke J, Vohmann C, Katalinic A, Nennecke A, Rensing M, et al. Survival of malignant mesothelioma and other rare thoracic cancers in Germany and the United States: A population-based study. *Int J Cancer*. 2020 Sept 15;147(6):1548–58.
357. Reinert C, Gerken M, Rathberger K, Krueger K, Klinkhammer-Schalke M, Lindberg-Scharf P, et al. Single-institution cross-sectional study to evaluate need for information and need for referral to psychooncology care in association with depression in brain tumor patients and their family caregivers. *BMC Psychol*. 2020 Sept 10;8(1):96.
358. Teufel A, Gerken M, Fürst A, Ebert M, Hohenthanner I, Klinkhammer-Schalke M. Benefit of adjuvant chemotherapy in high-risk colon cancer: A 17-year population-based analysis of 6131 patients with Union for International Cancer Control stage II T4N0M0 colon cancer. *Eur J Cancer*. 2020 Sept;137:148–60.
359. Sant M, Meneghini E, Bastos J, Rossi PG, Guevara M, Innos K, et al. Endocrine treatment and incidence of relapse in women with oestrogen receptor-positive breast cancer in Europe: a population-based study. *Breast Cancer Res Treat*. 2020 Sept;183(2):439–50.
360. Kowalski C, Albert US, Baumann W, Carl EG, Ernstmann N, Hermes-Moll K, et al. [DNVF Memorandum Health Services Research in Oncology]. *Gesundheitswesen*. 2020 Sept;82(8–09):e108–21.
361. Gebauer A, Barlag H, Wesselmann S, Biedenweg L, Weitmann K, Klinkhammer-Schalke M, et al. [Evaluation of Quality Indicators of Evidence-Based Guidelines Using ADT/GEKID Base Dataset and its Organ-Specific Modules]. *Gesundheitswesen*. 2020 Sept;82(8–09):710–5.
362. Jansen L, Holleczer B, Kraywinkel K, Weberpals J, Schröder CC, Eberle A, et al. Divergent Patterns and Trends in Breast Cancer Incidence, Mortality and Survival Among Older

Women in Germany and the United States. *Cancers (Basel)*. 2020 Aug 26;12(9).

363. Hellmund P, Schmitt J, Roessler M, Meier F, Schoffer O. Targeted and Checkpoint Inhibitor Therapy of Metastatic Malignant Melanoma in Germany, 2000-2016. *Cancers (Basel)*. 2020 Aug 20;12(9).
364. Katalinic A, Eisemann N, Kraywinkel K, Noftz MR, Hübner J. Breast cancer incidence and mortality before and after implementation of the German mammography screening program. *Int J Cancer*. 2020 Aug 1;147(3):709–18.
365. Spanier G, Böttcher J, Gerken M, Fischer R, Roth G, Lehn P, et al. Prognostic value of perioperative red blood cell transfusion and anemia on survival and recurrence in oral squamous cell carcinoma. *Oral Oncol*. 2020 Aug;107:104773.
366. Brunssen A, Jansen L, Eisemann N, Waldmann A, Weberpals J, Kraywinkel K, et al. Long-term relative survival from melanoma in Germany 1997-2013. *Melanoma Res*. 2020 Aug;30(4):386–95.
367. Minicozzi P, Vicentini M, Innos K, Castro C, Guevara M, Stracci F, et al. Comorbidities, timing of treatments, and chemotherapy use influence outcomes in stage III colon cancer: A population-based European study. *Eur J Surg Oncol*. 2020 June;46(6):1151–9.
368. Hübner J, Katalinic A, Waldmann A, Kraywinkel K. Long-term Incidence and Mortality Trends for Breast Cancer in Germany. *Geburtshilfe Frauenheilkd*. 2020 June;80(6):611–8.
369. Klinkhammer-Schalke M, Steinger B, Koller M, Zeman F, Fürst A, Gump J, et al. Diagnosing deficits in quality of life and providing tailored therapeutic options: Results of a randomised trial in 220 patients with colorectal cancer. *Eur J Cancer*. 2020 May;130:102–13.
370. Prantl L, Gerken M, Zeman F, Leitzmann M, Koller M, Klinkhammer-Schalke M, et al. Incidence of Anaplastic Large Cell Lymphoma and Breast-Implant-Associated Lymphoma- An Analysis of a Certified Tumor Registry over 17 Years. *J Clin Med*. 2020 Apr 25;9(5).
371. Papathemelis T, Oppermann H, Grafl S, Gerken M, Pauer A, Scharl S, et al. Long-term outcome of patients with intermediate- and high-risk endometrial cancer after pelvic and paraaortic lymph node dissection: a comparison of laparoscopic vs. open procedure. *J Cancer Res Clin Oncol*. 2020 Apr;146(4):961–9.
372. Hammersen F, Pursche T, Fischer D, Katalinic A, Waldmann A. Use of Complementary and Alternative Medicine among Young Patients with Breast Cancer. *Breast Care (Basel)*. 2020 Apr;15(2):163–70.
373. Finke I, Behrens G, Schwettmann L, Gerken M, Pritzkeleit R, Holleczeck B, et al. Socioeconomic differences and lung cancer survival in Germany: Investigation based on population-based clinical cancer registration. *Lung Cancer*. 2020 Apr;142:1–8.

374. Papathemelis T, Scharl A, Anapolski M, C Inwald E, Ignatov A, Ortmann O, et al. Value of indocyanine green pelvic lymph node mapping in the surgical approach of cervical cancer. *Arch Gynecol Obstet*. 2020 Mar;301(3):787–92.
375. Arndt V, Holleczeck B, Kajüter H, Luttmann S, Nennecke A, Zeissig SR, et al. Data from Population-based Cancer Registration for Secondary Data Analysis: Methodological Challenges and Perspectives. *Gesundheitswesen*. 2020 Mar;82(S 01):S62–71.
376. Schmuck R, Gerken M, Teegen EM, Krebs I, Klinkhammer-Schalke M, Aigner F, et al. Gender comparison of clinical, histopathological, therapeutic and outcome factors in 185,967 colon cancer patients. *Langenbecks Arch Surg*. 2020 Feb;405(1):71–80.
377. Bielska-Lasota M, Rossi S, Krzyżak M, Haelens A, Domenic A, De Angelis R, et al. Reasons for low cervical cancer survival in new accession European Union countries: a EURO CARE-5 study. *Arch Gynecol Obstet*. 2020 Feb;301(2):591–602.
378. Stangl S, Haas K, Eichner FA, Grau A, Selig U, Ludwig T, et al. Development and proof-of-concept of a multicenter, patient-centered cancer registry for breast cancer patients with metastatic disease-the ‘Breast cancer care for patients with metastatic disease’ (BRE-4-MED) registry. *Pilot Feasibility Stud*. 2020;6:11.
379. Jansen L, Behrens G, Finke I, Maier W, Gerken M, Pritzkuleit R, et al. Area-Based Socioeconomic Inequalities in Colorectal Cancer Survival in Germany: Investigation Based on Population-Based Clinical Cancer Registration. *Front Oncol*. 2020;10:857.
380. Sophia Rudolph CE, Katalinic A. [Baseline Incidence of HPV-Associated Invasive and in Situ Cancers in Germany Prior to Potential Vaccination Effects]. *Gesundheitswesen*. 2019 Dec;81(12):993–1000.
381. Hübner J, Hübner F, Terheyden P, Katalinic A. [Turning point in skin cancer mortality : An analysis of the trend in Germany from 1998 to 2017]. *Hautarzt*. 2019 Dec;70(12):989–92.
382. Rudolph C, Petersen GS, Pritzkuleit R, Storm H, Katalinic A. The acceptance and applicability of a patient-reported experience measurement tool in oncological care: a descriptive feasibility study in northern Germany. *BMC Health Serv Res*. 2019 Nov 1;19(1):786.
383. Völkel V, Draeger T, Gerken M, Fürst A, Klinkhammer-Schalke M. [Long-Term Survival of Patients with Colon and Rectum Carcinomas: Is There a Difference Between Cancer Centers and Non-Certified Hospitals?]. *Gesundheitswesen*. 2019 Oct;81(10):801–7.
384. Völkel V, Draeger T, Schnitzbauer V, Gerken M, Benz S, Klinkhammer-Schalke M, et al. Surgical treatment of rectal cancer patients aged 80 years and older-a German nationwide analysis comparing short- and long-term survival after laparoscopic and open tumor resection. *Eur J Surg Oncol*. 2019 Sept;45(9):1607–12.
385. Deck R, Babaev V, Katalinic A. [Reasons for the Non-Utilisation of an Oncological

Rehabilitation. Results of a Written Survey with Patients of Oncological Healthcare Centers]. *Rehabilitation (Stuttg)*. 2019 Aug;58(4):243–52.

386. Voelkel V, Draeger T, Groothuis-Oudshoorn CGM, de Munck L, Hueting T, Gerken M, et al. Predicting the risk of locoregional recurrence after early breast cancer: an external validation of the Dutch INFLUENCE-nomogram with clinical cancer registry data from Germany. *J Cancer Res Clin Oncol*. 2019 July;145(7):1823–33.
387. Garbe C, Keim U, Eigentler TK, Amaral T, Katalinic A, Holleczek B, et al. Time trends in incidence and mortality of cutaneous melanoma in Germany. *J Eur Acad Dermatol Venereol*. 2019 July;33(7):1272–80.
388. Minicozzi P, Van Eycken L, Molinie F, Innos K, Guevara M, Marcos-Gragera R, et al. Comorbidities, age and period of diagnosis influence treatment and outcomes in early breast cancer. *Int J Cancer*. 2019 May 1;144(9):2118–27.
389. Papathemelis T, Knobloch S, Gerken M, Scharl A, Anapolski M, Ignatov A, et al. Impact of nodal status and treatment strategy on overall survival in advanced stage cervical cancer. *J Cancer Res Clin Oncol*. 2019 May;145(5):1369–76.
390. Draeger T, Völkel V, Schnitzbauer V, Gerken M, Benz S, Klinkhammer-Schalke M, et al. Laparoscopic and open resection of rectal cancer-is age an effect modifier for short- and long-term survival? *Int J Colorectal Dis*. 2019 May;34(5):821–8.
391. Wimmer T, Ortmann O, Gerken M, Klinkhammer-Schalke M, Koelbl O, Inwald EC. Adherence to guidelines and benefit of adjuvant radiotherapy in patients with invasive breast cancer: results from a large population-based cohort study of a cancer registry. *Arch Gynecol Obstet*. 2019 Apr;299(4):1131–40.
392. Hübner J, Lewin P, Pritzkeleit R, Eisemann N, Maier W, Katalinic A. Colorectal cancer screening by colonoscopy and trends in disease-specific mortality: a population-based ecological study of 358 German districts. *Int J Colorectal Dis*. 2019 Apr;34(4):599–605.
393. Brunssen A, Jansen L, Eisemann N, Waldmann A, Weberpals J, Kraywinkel K, et al. A population-based registry study on relative survival from melanoma in Germany stratified by tumor thickness for each histologic subtype. *J Am Acad Dermatol*. 2019 Apr;80(4):938–46.
394. Seliger C, Lubert C, Gerken M, Schaertl J, Proescholdt M, Riemenschneider MJ, et al. Use of metformin and survival of patients with high-grade glioma. *Int J Cancer*. 2019 Jan 15;144(2):273–80.
395. Jobs A, Schwind J, Katalinic A, Babaev V, Tilz RR, Rausch S, et al. Prognostic significance of atrial fibrillation in acute decompensated heart failure with reduced versus preserved ejection fraction. *Clin Res Cardiol*. 2019 Jan;108(1):74–82.
396. Albert US, Schreier I. [S3 guideline breast cancer: update on early detection, and

- mammography screening]. *Radiologe*. 2019 Jan;59(1):13–8.
397. Hübner J, Eisemann N, Brunßen A, Katalinic A. [Skin cancer screening in Germany: review after ten years]. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz*. 2018 Dec;61(12):1536–43.
 398. Hammersen F, Pursche T, Fischer D, Katalinic A, Waldmann A. [Signs of social inequality in information seeking and evaluation of information among young women with breast cancer - results of a cohort study]. *Z Evid Fortbild Qual Gesundhwes*. 2018 Dec;139:10–6.
 399. Wöckel A, Festl J, Stüber T, Brust K, Krockenberger M, Heuschmann PU, et al. Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer. *Geburtshilfe Frauenheilkd*. 2018 Nov;78(11):1056–88.
 400. Piso P, Stierstorfer K, Gerken M, Klinkhammer-Schalke M. Benefit of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy in patients with isolated peritoneal metastases from colorectal cancer. *Int J Colorectal Dis*. 2018 Nov;33(11):1559–67.
 401. Hübner J, Waldmann A, Eisemann N, Noftz M, Geller AC, Weinstock MA, et al. Association between risk factors and detection of cutaneous melanoma in the setting of a population-based skin cancer screening. *Eur J Cancer Prev*. 2018 Nov;27(6):563–9.
 402. Wöckel A, Festl J, Stüber T, Brust K, Stangl S, Heuschmann PU, et al. Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer. *Geburtshilfe Frauenheilkd*. 2018 Oct;78(10):927–48.
 403. Völkel V, Draeger T, Gerken M, Klinkhammer-Schalke M, Fürst A. Long-term oncologic outcomes after laparoscopic vs. open colon cancer resection: a high-quality population-based analysis in a Southern German district. *Surg Endosc*. 2018 Oct;32(10):4138–47.
 404. Papatthemelis T, Hassas D, Gerken M, Klinkhammer-Schalke M, Scharl A, Lux MP, et al. Is there a benefit of lymphadenectomy for overall and recurrence-free survival in type I FIGO IB G1-2 endometrial carcinoma? A retrospective population-based cohort analysis. *J Cancer Res Clin Oncol*. 2018 Oct;144(10):2019–27.
 405. Draeger T, Völkel V, Gerken M, Klinkhammer-Schalke M, Fürst A. Long-term oncologic outcomes after laparoscopic versus open rectal cancer resection: a high-quality population-based analysis in a Southern German district. *Surg Endosc*. 2018 Oct;32(10):4096–104.
 406. Katalinic A. The Burden of Cancer in Germany. *Dtsch Arztebl Int*. 2018 Sept 3;115(35–36):569–70.

407. Eisemann N, Waldmann A, Holleczeck B, Katalinic A. Observed and expected mortality in the German skin cancer screening pilot project SCREEN. *J Med Screen*. 2018 Sept;25(3):166–8.
408. Pulte D, Weberpals J, Schröder CC, Emrich K, Holleczeck B, Katalinic A, et al. Survival of patients with hepatobiliary tract and duodenal cancer sites in Germany and the United States in the early 21st century. *Int J Cancer*. 2018 July 15;143(2):324–32.
409. Reinert C, Rathberger K, Klinkhammer-Schalke M, Kölbl O, Proescholdt M, Riemenschneider MJ, et al. Information needs and requirements in patients with brain tumours and their relatives. *J Neurooncol*. 2018 June;138(2):407–15.
410. Jobs A, Simon R, de Waha S, Rogacev K, Katalinic A, Babaev V, et al. Pneumonia and inflammation in acute decompensated heart failure: a registry-based analysis of 1939 patients. *Eur Heart J Acute Cardiovasc Care*. 2018 June;7(4):362–70.
411. Scharl S, Papatthemelis T, Kronberger K, Gerken M, Scharl A, Kölbl O, et al. Does post-operative radiochemotherapy improve survival in high-grade endometrial cancer patients? Results of a population-based cohort analysis of a cancer registry. *Arch Gynecol Obstet*. 2018 May;297(5):1245–53.
412. Liebig-Hörl G, Puchner C, Gerken M, Klinkhammer-Schalke M, Fürst A. [Treatment strategy for early stage rectal cancer (T1 carcinoma)]. *Chirurg*. 2018 May;89(5):358–64.
413. Munker S, Gerken M, Fest P, Ott C, Schnoy E, Fichtner-Feigl S, et al. Chemotherapy for metastatic colon cancer: No effect on survival when the dose is reduced due to side effects. *BMC Cancer*. 2018 Apr 23;18(1):455.
414. Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. *Lancet*. 2018 Mar 17;391(10125):1023–75.
415. Chen T, Brenner H, Fallah M, Jansen L, Castro FA, Geiss K, et al. Response: Methods for second primary cancers evaluation have to be standardized. *Int J Cancer*. 2018 Mar 15;142(6):1286–7.
416. Sacchetto L, Zanetti R, Comber H, Bouchardy C, Brewster DH, Broganelli P, et al. Trends in incidence of thick, thin and in situ melanoma in Europe. *Eur J Cancer*. 2018 Mar;92:108–18.
417. Jansen L, Buttmann-Schweiger N, Listl S, Ressing M, Holleczeck B, Katalinic A, et al. Differences in incidence and survival of oral cavity and pharyngeal cancers between Germany and the United States depend on the HPV-association of the cancer site. *Oral Oncol*. 2018 Jan;76:8–15.
418. Seliger C, Schaertl J, Gerken M, Lubert C, Proescholdt M, Riemenschneider MJ, et al. Use

of statins or NSAIDs and survival of patients with high-grade glioma. PLoS One. 2018;13(12):e0207858.

419. Papathemelis T, Jablonski E, Scharl A, Hauzenberger T, Gerken M, Klinkhammer-Schalke M, et al. Sentinel Lymph Node Biopsy in Breast Cancer Patients by Means of Indocyanine Green Using the Karl Storz VITOM® Fluorescence Camera. Biomed Res Int. 2018;2018:6251468.
420. Ott C, Gerken M, Hirsch D, Fest P, Fichtner-Feigl S, Munker S, et al. Advanced Mucinous Colorectal Cancer: Epidemiology, Prognosis and Efficacy of Chemotherapeutic Treatment. Digestion. 2018;98(3):143–52.
421. Hoebel J, Kroll LE, Fiebig J, Lampert T, Katalinic A, Barnes B, et al. Socioeconomic Inequalities in Total and Site-Specific Cancer Incidence in Germany: A Population-Based Registry Study. Front Oncol. 2018;8:402.
422. Haj A, Doenitz C, Schebesch KM, Ehrensberger D, Hau P, Putnik K, et al. Extent of Resection in Newly Diagnosed Glioblastoma: Impact of a Specialized Neuro-Oncology Care Center. Brain Sci. 2017 Dec 25;8(1).
423. Chen T, Brenner H, Fallah M, Jansen L, Castro FA, Geiss K, et al. Risk of second primary cancers in women diagnosed with endometrial cancer in German and Swedish cancer registries. Int J Cancer. 2017 Dec 1;141(11):2270–80.
424. Pritzkeleit R, Eisemann N, Katalinic A. [The cartographic depiction of regional variation in morbidity : Data analysis options using the example of the small-scale cancer atlas for Schleswig-Holstein]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2017 Dec;60(12):1319–27.
425. Papathemelis T, Scharl S, Kronberger K, Gerken M, Scharl A, Pauer A, et al. Survival benefit of pelvic and paraaortic lymphadenectomy in high-grade endometrial carcinoma: a retrospective population-based cohort analysis. J Cancer Res Clin Oncol. 2017 Dec;143(12):2555–62.
426. Matz M, Coleman MP, Sant M, Chirlaque MD, Visser O, Gore M, et al. Erratum to ‘The histology of ovarian cancer: Worldwide distribution and implications for international survival comparisons (CONCORD-2)’ [Gynecol. Oncol. 144 (2017) 405-413]. Gynecol Oncol. 2017 Dec;147(3):726.
427. Matz M, Coleman MP, Carreira H, Salmerón D, Chirlaque MD, Allemani C. Erratum to ‘Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2)’ [Gynecol. Oncol. 144 (2017) 396-404]. Gynecol Oncol. 2017 Dec;147(3):725.
428. Pulte D, Weberpals J, Jansen L, Luttmann S, Holleczer B, Nennecke A, et al. Survival for patients with rare haematologic malignancies: Changes in the early 21st century. Eur J Cancer. 2017 Oct;84:81–7.

429. Minicozzi P, Innos K, Sánchez MJ, Trama A, Walsh PM, Marcos-Gragera R, et al. Quality analysis of population-based information on cancer stage at diagnosis across Europe, with presentation of stage-specific cancer survival estimates: A EUROCARE-5 study. *Eur J Cancer*. 2017 Oct;84:335–53.
430. Leiter U, Keim U, Eigentler T, Katalinic A, Holleczek B, Martus P, et al. Incidence, Mortality, and Trends of Nonmelanoma Skin Cancer in Germany. *J Invest Dermatol*. 2017 Sept;137(9):1860–7.
431. Holleczek B, Katalinic A. Toward a comprehensive cancer registration in Germany. *Eur J Cancer Prev*. 2017 Sept;26 Joining forces for better cancer registration in Europe:S132–8.
432. Gatta G, Peris-Bonet R, Visser O, Stiller C, Marcos-Gragera R, Sánchez MJ, et al. Geographical variability in survival of European children with central nervous system tumours. *Eur J Cancer*. 2017 Sept;82:137–48.
433. Jobs A, Brünjes K, Katalinic A, Babaev V, Desch S, Reppel M, et al. Inferior vena cava diameter in acute decompensated heart failure as predictor of all-cause mortality. *Heart Vessels*. 2017 July;32(7):856–64.
434. Schmick A, Juergensen M, Rohde V, Katalinic A, Waldmann A. Assessing health-related quality of life in urology - a survey of 4500 German urologists. *BMC Urol*. 2017 June 19;17(1):46.
435. Weberpals J, Pulte D, Jansen L, Luttmann S, Holleczek B, Nennecke A, et al. Survival of patients with lymphoplasmacytic lymphoma and solitary plasmacytoma in Germany and the United States of America in the early 21(st) century. *Haematologica*. 2017 June;102(6):e229–32.
436. Steliarova-Foucher E, Colombet M, Ries LAG, Moreno F, Dolya A, Bray F, et al. International incidence of childhood cancer, 2001-10: a population-based registry study. *Lancet Oncol*. 2017 June;18(6):719–31.
437. Klinkhammer-Schalke M, Steinger B, Koller M, Lindberg P. [Interventions to improve quality of life in oncological patients]. *Z Evid Fortbild Qual Gesundhwes*. 2017 May;122:48–52.
438. Inwald EC, Ortmann O, Koller M, Zeman F, Hofstädter F, Evert M, et al. Screening-relevant age threshold of 70 years and older is a stronger determinant for the choice of adjuvant treatment in breast cancer patients than tumor biology. *Breast Cancer Res Treat*. 2017 May;163(1):119–30.
439. Dal Maso L, Tavilla A, Pacini F, Serraino D, van Dijk BAC, Chirlaque MD, et al. Survival of 86,690 patients with thyroid cancer: A population-based study in 29 European countries from EUROCARE-5. *Eur J Cancer*. 2017 May;77:140–52.
440. Bonaventure A, Harewood R, Stiller CA, Gatta G, Clavel J, Stefan DC, et al. Worldwide

comparison of survival from childhood leukaemia for 1995-2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries. *Lancet Haematol*. 2017 May;4(5):e202–17.

441. Winter A, Sirri E, Jansen L, Wawroschek F, Kieschke J, Castro FA, et al. Comparison of prostate cancer survival in Germany and the USA: can differences be attributed to differences in stage distributions? *BJU Int*. 2017 Apr;119(4):550–9.
442. Hager B, Kraywinkel K, Keck B, Katalinic A, Meyer M, Zeissig SR, et al. Increasing use of radical prostatectomy for locally advanced prostate cancer in the USA and Germany: a comparative population-based study. *Prostate Cancer Prostatic Dis*. 2017 Mar;20(1):61–6.
443. Matz M, Coleman MP, Sant M, Chirlaque MD, Visser O, Gore M, et al. The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2). *Gynecol Oncol*. 2017 Feb;144(2):405–13.
444. Matz M, Coleman MP, Carreira H, Salmerón D, Chirlaque MD, Allemani C. Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2). *Gynecol Oncol*. 2017 Feb;144(2):396–404.
445. Hübner J, Waldmann A, Geller AC, Weinstock MA, Eisemann N, Nofzt M, et al. Interval cancers after skin cancer screening: incidence, tumour characteristics and risk factors for cutaneous melanoma. *Br J Cancer*. 2017 Jan 17;116(2):253–9.
446. Brunssen A, Waldmann A, Eisemann N, Katalinic A. Impact of skin cancer screening and secondary prevention campaigns on skin cancer incidence and mortality: A systematic review. *J Am Acad Dermatol*. 2017 Jan;76(1):129-139.e10.
447. Lindberg P, Netter P, Koller M, Steinger B, Klinkhammer-Schalke M. Breast cancer survivors` recollection of their quality of life: Identifying determinants of recall bias in a longitudinal population-based trial. *PLoS One*. 2017;12(2):e0171519.
448. Hammersen F, Lewin P, Gebauer J, Kreitschmann-Andermahr I, Brabant G, Katalinic A, et al. Sleep quality and health-related quality of life among long-term survivors of (non-) Hodgkin lymphoma in Germany. *PLoS One*. 2017;12(11):e0187673.
449. Pulte D, Jansen L, Castro FA, Krilaviciute A, Katalinic A, Barnes B, et al. Survival in patients with acute myeloblastic leukemia in Germany and the United States: Major differences in survival in young adults. *Int J Cancer*. 2016 Sept 15;139(6):1289–96.
450. Liu L, O'Donnell P, Sullivan R, Katalinic A, Moser L, de Boer A, et al. Cancer in Europe: Death sentence or life sentence? *Eur J Cancer*. 2016 Sept;65:150–5.
451. Sirri E, Castro FA, Kieschke J, Jansen L, Emrich K, Gondos A, et al. Recent Trends in Survival of Patients With Pancreatic Cancer in Germany and the United States. *Pancreas*. 2016 July;45(6):908–14.

452. Merz M, Jansen L, Castro FA, Hillengass J, Salwender H, Weisel K, et al. Survival of elderly patients with multiple myeloma-Effect of upfront autologous stem cell transplantation. *Eur J Cancer*. 2016 July;62:1–8.
453. Peller M, Katalinic A, Wollenberg B, Teudt IU, Meyer JE. Epidemiology of laryngeal carcinoma in Germany, 1998-2011. *Eur Arch Otorhinolaryngol*. 2016 June;273(6):1481–7.
454. Eisemann N, Schnoor M, Katalinic A. Prediction of chronic lymphocytic leukaemia incidence in Germany and of patients ineligible for standard chemotherapy. *Hematol Oncol*. 2016 June;34(2):93–101.
455. Eisemann N, Jansen L, Castro FA, Chen T, Eberle A, Nennecke A, et al. Survival with nonmelanoma skin cancer in Germany. *Br J Dermatol*. 2016 Apr;174(4):778–85.
456. Pulte D, Castro FA, Jansen L, Luttmann S, Holleczer B, Nennecke A, et al. Trends in survival of chronic lymphocytic leukemia patients in Germany and the USA in the first decade of the twenty-first century. *J Hematol Oncol*. 2016 Mar 22;9:28.
457. Chen T, Fallah M, Brenner H, Jansen L, Mai EK, Castro FA, et al. Risk of Second Primary Cancers in Multiple Myeloma Survivors in German and Swedish Cancer Registries. *Sci Rep*. 2016 Feb 24;6:22084.
458. Brenner H, Schrotz-King P, Holleczer B, Katalinic A, Hoffmeister M. Declining Bowel Cancer Incidence and Mortality in Germany. *Dtsch Arztebl Int*. 2016 Feb 19;113(7):101–6.
459. Katalinic A. [Improved prognosis for symptom-free older women with mammography-detected breast cancer?]. *Strahlenther Onkol*. 2016 Feb;192(2):130–2.
460. Heywang-Köbrunner SH, Schreer I, Hacker A, Nofzt MR, Katalinic A. Conclusions for mammography screening after 25-year follow-up of the Canadian National Breast Cancer Screening Study (CNBSS). *Eur Radiol*. 2016 Feb;26(2):342–50.
461. Brenner H, Castro FA, Eberle A, Emrich K, Holleczer B, Katalinic A, et al. Death certificate only proportions should be age adjusted in studies comparing cancer survival across populations and over time. *Eur J Cancer*. 2016 Jan;52:102–8.
462. Adzersen KH, Friedrich S, Becker N. Are epidemiological data on lymphoma incidence comparable? Results from an application of the coding recommendations of WHO, InterLymph, ENCR and SEER to a cancer registry dataset. *J Cancer Res Clin Oncol*. 2016 Jan;142(1):167–75.
463. Chen T, Fallah M, Jansen L, Castro FA, Krilaviciute A, Katalinic A, et al. Distribution and risk of the second discordant primary cancers combined after a specific first primary cancer in German and Swedish cancer registries. *Cancer Lett*. 2015 Dec 1;369(1):152–66.
464. Eberle A, Jansen L, Castro F, Krilaviciute A, Luttmann S, Emrich K, et al. Lung cancer survival in Germany: A population-based analysis of 132,612 lung cancer patients. *Lung*

Cancer. 2015 Dec;90(3):528–33.

465. Mounier M, Bossard N, Remontet L, Belot A, Minicozzi P, De Angelis R, et al. Changes in dynamics of excess mortality rates and net survival after diagnosis of follicular lymphoma or diffuse large B-cell lymphoma: comparison between European population-based data (EUROCARE-5). *Lancet Haematol*. 2015 Nov;2(11):e481-491.
466. Haug U, Rösch T, Hoffmeister M, Katalinic A, Brenner H, Becker N. [Implementing an Organised Colorectal Cancer Screening Programme in Germany: Opportunities and Challenges]. *Gesundheitswesen*. 2015 Nov;77(11):869–74.
467. Visser O, Ardanaz E, Botta L, Sant M, Tavilla A, Minicozzi P. Survival of adults with primary malignant brain tumours in Europe; Results of the EUROCARE-5 study. *Eur J Cancer*. 2015 Oct;51(15):2231–41.
468. Trama A, Foschi R, Larrañaga N, Sant M, Fuentes-Raspall R, Serraino D, et al. Survival of male genital cancers (prostate, testis and penis) in Europe 1999-2007: Results from the EUROCARE-5 study. *Eur J Cancer*. 2015 Oct;51(15):2206–16.
469. Sant M, Chirlaque Lopez MD, Agresti R, Sánchez Pérez MJ, Holleczech B, Bielska-Lasota M, et al. Survival of women with cancers of breast and genital organs in Europe 1999-2007: Results of the EUROCARE-5 study. *Eur J Cancer*. 2015 Oct;51(15):2191–205.
470. Rossi S, Baili P, Capocaccia R, Caldora M, Carrani E, Minicozzi P, et al. The EUROCARE-5 study on cancer survival in Europe 1999-2007: Database, quality checks and statistical analysis methods. *Eur J Cancer*. 2015 Oct;51(15):2104–19.
471. Pulte D, Jansen L, Castro FA, Emrich K, Katalinic A, Holleczech B, et al. Trends in survival of multiple myeloma patients in Germany and the United States in the first decade of the 21st century. *Br J Haematol*. 2015 Oct;171(2):189–96.
472. Marcos-Gragera R, Mallone S, Kiemeny LA, Vilardell L, Malats N, Allory Y, et al. Urinary tract cancer survival in Europe 1999-2007: Results of the population-based study EUROCARE-5. *Eur J Cancer*. 2015 Oct;51(15):2217–30.
473. Lepage C, Capocaccia R, Hackl M, Lemmens V, Molina E, Pierannunzio D, et al. Survival in patients with primary liver cancer, gallbladder and extrahepatic biliary tract cancer and pancreatic cancer in Europe 1999-2007: Results of EUROCARE-5. *Eur J Cancer*. 2015 Oct;51(15):2169–78.
474. Holleczech B, Rossi S, Domenic A, Innos K, Minicozzi P, Francisci S, et al. On-going improvement and persistent differences in the survival for patients with colon and rectum cancer across Europe 1999-2007 - Results from the EUROCARE-5 study. *Eur J Cancer*. 2015 Oct;51(15):2158–68.
475. Gatta G, Botta L, Sánchez MJ, Anderson LA, Pierannunzio D, Licitra L. Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: The

- EUROCARE-5 population-based study. *Eur J Cancer*. 2015 Oct;51(15):2130–43.
476. Francisci S, Minicozzi P, Pierannunzio D, Ardanaz E, Eberle A, Grimsrud TK, et al. Survival patterns in lung and pleural cancer in Europe 1999-2007: Results from the EUROCARE-5 study. *Eur J Cancer*. 2015 Oct;51(15):2242–53.
 477. Fick EM, Katalinic A, Waldmann A. The Frequency of and Risk Factors for the Use of Bisphosphonates in the Adjuvant Setting of Primary Breast Cancer in Germany. *Cancer Res Treat*. 2015 Oct;47(4):747–56.
 478. De Angelis R, Minicozzi P, Sant M, Dal Maso L, Brewster DH, Osca-Gelis G, et al. Survival variations by country and age for lymphoid and myeloid malignancies in Europe 2000-2007: Results of EUROCARE-5 population-based study. *Eur J Cancer*. 2015 Oct;51(15):2254–68.
 479. Crocetti E, Mallone S, Robsahm TE, Gavin A, Agius D, Ardanaz E, et al. Survival of patients with skin melanoma in Europe increases further: Results of the EUROCARE-5 study. *Eur J Cancer*. 2015 Oct;51(15):2179–90.
 480. Castro FA, Jansen L, Krilaviciute A, Katalinic A, Pulte D, Sirri E, et al. Survival of patients with gastric lymphoma in Germany and in the United States. *J Gastroenterol Hepatol*. 2015 Oct;30(10):1485–91.
 481. Baili P, Di Salvo F, Marcos-Gragera R, Siesling S, Mallone S, Santaquilani M, et al. Age and case mix-standardised survival for all cancer patients in Europe 1999-2007: Results of EUROCARE-5, a population-based study. *Eur J Cancer*. 2015 Oct;51(15):2120–9.
 482. Anderson LA, Tavilla A, Brenner H, Luttmann S, Navarro C, Gavin AT, et al. Survival for oesophageal, stomach and small intestine cancers in Europe 1999-2007: Results from EUROCARE-5. *Eur J Cancer*. 2015 Oct;51(15):2144–57.
 483. Katalinic A, Eisemann N, Waldmann A. Skin Cancer Screening in Germany. Documenting Melanoma Incidence and Mortality From 2008 to 2013. *Dtsch Arztebl Int*. 2015 Sept 18;112(38):629–34.
 484. Boniol M, Autier P, Gandini S. Melanoma mortality following skin cancer screening in Germany. *BMJ Open*. 2015 Sept 15;5(9):e008158.
 485. Peters E, Anzeneder T, Jackisch C, Dimpfl T, Kunz G, Katalinic A, et al. The Treatment of Primary Breast Cancer in Older Women With Adjuvant Therapy: A Retrospective Analysis of Data From Over 3000 Patients From the PATH Biobank, With Two-Year Follow-up. *Dtsch Arztebl Int*. 2015 Aug 31;112(35–36):577–84.
 486. Rudolph C, Schnoor M, Eisemann N, Katalinic A. Incidence trends of nonmelanoma skin cancer in Germany from 1998 to 2010. *J Dtsch Dermatol Ges*. 2015 Aug;13(8):788–97.
 487. Gebauer J, Fick EM, Waldmann A, Langer T, Kreitschmann-Andermahr I, Lehnert H, et al.

Self-reported endocrine late effects in adults treated for brain tumours, Hodgkin and non-Hodgkin lymphoma: a registry based study in Northern Germany. *Eur J Endocrinol*. 2015 Aug;173(2):139–48.

488. Lindberg P, Koller M, Steinger B, Lorenz W, Wyatt JC, Inwald EC, et al. Breast cancer survivors' recollection of their illness and therapy seven years after enrolment into a randomised controlled clinical trial. *BMC Cancer*. 2015 July 29;15:554.
489. Katalinic A. [Commentary on the article 'Skin cancer screening in Germany' by Blum et al]. *Hautarzt*. 2015 July;66(7):540–1.
490. Jansen L, Castro FA, Gondos A, Krilaviciute A, Barnes B, Eberle A, et al. Recent cancer survival in Germany: an analysis of common and less common cancers. *Int J Cancer*. 2015 June 1;136(11):2649–58.
491. Storm HH, Engholm G, Pritzkeleit R, Kejs AMT, Katalinic A, Dunst J, et al. Less pitfalls and variation in population based cancer survival comparisons within the European Union: Lessons from colorectal cancer patients in neighbouring regions in Denmark and Germany - The Fehmarn Belt project. *Eur J Cancer*. 2015 June;51(9):1188–98.
492. Hübner J, Noftz MR, Schnoor M, Katalinic A. [Erratum to: Screening for colorectal, skin, breast and prostate cancer. Essential knowledge for counseling]. *Internist (Berl)*. 2015 June;56(6):716.
493. Eisemann N, Nolte S, Schnoor M, Katalinic A, Rohde V, Waldmann A. The ProCaSP study: quality of life outcomes of prostate cancer patients after radiotherapy or radical prostatectomy in a cohort study. *BMC Urol*. 2015 Apr 10;15:28.
494. Hager B, Kraywinkel K, Keck B, Katalinic A, Meyer M, Zeissig SR, et al. Integrated prostate cancer centers might cause an overutilization of radiotherapy for low-risk prostate cancer: A comparison of treatment trends in the United States and Germany from 2004 to 2011. *Radiother Oncol*. 2015 Apr;115(1):90–5.
495. Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). *Lancet*. 2015 Mar 14;385(9972):977–1010.
496. Hermann S, Friedrich S, Haug U, Rohrmann S, Becker N, Kaaks R. Association between socioeconomic and demographic characteristics and utilization of colonoscopy in the EPIC-Heidelberg cohort. *Eur J Cancer Prev*. 2015 Mar;24(2):81–8.
497. Eisemann N, Waldmann A, Garbe C, Katalinic A. Development of a microsimulation of melanoma mortality for evaluating the effectiveness of population-based skin cancer screening. *Med Decis Making*. 2015 Feb;35(2):243–54.
498. Klinkhammer-Schalke M, Gerken M, Barlag H, Tillack A. [Quality management in

oncology supported by clinical cancer registries]. *Z Evid Fortbild Qual Gesundhwes*. 2015;109(6):452–8.

499. Katalinic A. [Cancer screening-- sense or nonsense?]. *Oncol Res Treat*. 2015;38 Suppl 3:12.
500. Hübner J, Noftz MR, Schnoor M, Katalinic A. [Screening for colorectal, skin, breast and prostate cancer. Essential knowledge for counseling]. *Internist (Berl)*. 2014 Oct;55(10):1171–81.
501. Kapsimalakou S, Waldmann A, Katalinic A, Grande-Nagel I, Fischer D, Barkhausen J, et al. Follow-up of probably benign lesions in non-screening breast diagnostics. *Arch Gynecol Obstet*. 2014 Sept;290(3):543–51.
502. Sant M, Minicozzi P, Mounier M, Anderson LA, Brenner H, Holleczeck B, et al. Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EURO CARE-5, a population-based study. *Lancet Oncol*. 2014 Aug;15(9):931–42.
503. Jansen L, Eberle A, Emrich K, Gondos A, Holleczeck B, Kajüter H, et al. Socioeconomic deprivation and cancer survival in Germany: an ecological analysis in 200 districts in Germany. *Int J Cancer*. 2014 June 15;134(12):2951–60.
504. Nennecke A, Geiss K, Hentschel S, Vettorazzi E, Jansen L, Eberle A, et al. Survival of cancer patients in urban and rural areas of Germany--a comparison. *Cancer Epidemiol*. 2014 June;38(3):259–65.
505. Eisemann N, Waldmann A, Rohde V, Katalinic A. Quality of life in partners of patients with localised prostate cancer. *Qual Life Res*. 2014 June;23(5):1557–68.
506. Waldmann A, Anzeneder T, Katalinic A. Patients and Methods of the PATH Biobank - A Resource for Breast Cancer Research. *Geburtshilfe Frauenheilkd*. 2014 Apr;74(4):361–9.
507. Pulte D, Jansen L, Gondos A, Emrich K, Holleczeck B, Katalinic A, et al. Improved population level survival in younger Hodgkin lymphoma patients in Germany in the early 21st century. *Br J Haematol*. 2014 Mar;164(6):851–7.
508. Schönfeld I, Kraywinkel K. [Epidemiological cancer data online: an overview of information service in Germany and Europe]. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz*. 2014 Jan;57(1):22–6.
509. Gatta G, Botta L, Rossi S, Aareleid T, Bielska-Lasota M, Clavel J, et al. Childhood cancer survival in Europe 1999-2007: results of EURO CARE-5--a population-based study. *Lancet Oncol*. 2014 Jan;15(1):35–47.
510. Eisemann N, Waldmann A, Geller AC, Weinstock MA, Volkmer B, Greinert R, et al. Non-melanoma skin cancer incidence and impact of skin cancer screening on incidence. *J Invest Dermatol*. 2014 Jan;134(1):43–50.
511. Eisemann N, Waldmann A, Katalinic A. [Incidence of melanoma and changes in stage-

specific incidence after implementation of skin cancer screening in Schleswig-Holstein]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2014 Jan;57(1):77–83.

512. De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, et al. Cancer survival in Europe 1999-2007 by country and age: results of EURO CARE--5-a population-based study. *Lancet Oncol*. 2014 Jan;15(1):23–34.
513. Zanetti R, Sacchetto L, Calvia M, Bordoni A, Hakulinen T, Znaor A, et al. Economic evaluation of cancer registration in Europe. *J Registry Manag*. 2014 Spring;41(1):31–7.
514. Pulte D, Jansen L, Gondos A, Katalinic A, Barnes B, Ressing M, et al. Survival of adults with acute lymphoblastic leukemia in Germany and the United States. *PLoS One*. 2014;9(1):e85554.
515. Breitbart EW, Choudhury K, Anders MP, Volkmer B, Greinert R, Katalinic A, et al. Benefits and risks of skin cancer screening. *Oncol Res Treat*. 2014;37 Suppl 3:38–47.
516. Schnoor M, Hallof A, Hergert-Lüder D, Katalinic A, Waldmann A. [Reasons for non-participation in mammography screening--a survey in Schleswig-Holstein, Germany]. *Dtsch Med Wochenschr*. 2013 Nov;138(45):2289–94.
517. Greiner F, Nolte S, Waldmann A, Katalinic A, Breitbart EW. [Collection and processing of personal data to evaluate cancer screening programmes - results of a survey of the German population in light of the bill 'early detection of cancer and cancer registries']. *Gesundheitswesen*. 2013 Nov;75(11):751–3.
518. Gondos A, Hiripi E, Holleczeck B, Luttmann S, Eberle A, Brenner H. Survival among adolescents and young adults with cancer in Germany and the United States: an international comparison. *Int J Cancer*. 2013 Nov;133(9):2207–15.
519. Liu H, Hemminki K, Sundquist J, Holleczeck B, Katalinic A, Emrich K, et al. A population-based comparison of second primary cancers in Germany and Sweden between 1997 and 2006: clinical implications and etiologic aspects. *Cancer Med*. 2013 Oct;2(5):718–24.
520. Pulte D, Barnes B, Jansen L, Eisemann N, Emrich K, Gondos A, et al. Population level survival of patients with chronic myelocytic leukemia in Germany compared to the US in the early 21st century. *J Hematol Oncol*. 2013 Sept 16;6(1):70.
521. Stang A, Jansen L, Trabert B, Rusner C, Eberle A, Katalinic A, et al. Survival after a diagnosis of testicular germ cell cancers in Germany and the United States, 2002-2006: a high resolution study by histology and age. *Cancer Epidemiol*. 2013 Aug;37(4):492–7.
522. Rusner C, Trabert B, Katalinic A, Kieschke J, Emrich K, Stang A. Incidence patterns and trends of malignant gonadal and extragonadal germ cell tumors in Germany, 1998-2008. *Cancer Epidemiol*. 2013 Aug;37(4):370–3.
523. Inwald EC, Klinkhammer-Schalke M, Hofstädter F, Zeman F, Koller M, Gerstenhauer M, et

- al. Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. *Breast Cancer Res Treat*. 2013 June;139(2):539–52.
524. Pulte D, Jansen L, Gondos A, Emrich K, Holleczeck B, Katalinic A, et al. Survival of patients with non-Hodgkin lymphoma in Germany in the early 21st century. *Leuk Lymphoma*. 2013 May;54(5):979–85.
 525. Liu H, Hemminki K, Sundquist J, Holleczeck B, Katalinic A, Emrich K, et al. Second primary cancers after cancer of unknown primary in Sweden and Germany: efficacy of the modern work-up. *Eur J Cancer Prev*. 2013 May;22(3):210–4.
 526. Fick EM, Anzeneder T, Katalinic A, Waldmann A. Bisphosphonates and their Role in Therapy for Breast Cancer - Results from the PATH Biobank. *Geburtshilfe Frauenheilkd*. 2013 May;73(5):412–21.
 527. Waldmann A, Eisemann N, Katalinic A. Epidemiology of Malignant Cervical, Corpus Uteri and Ovarian Tumours - Current Data and Epidemiological Trends. *Geburtshilfe Frauenheilkd*. 2013 Feb;73(2):123–9.
 528. Nennecke A, Barnes B, Brenner H, Eberle A, Emrich K, Eisemann N, et al. [Data quality or differences in oncological care? - standards of reporting for cancer survival analyses based on registry data]. *Gesundheitswesen*. 2013 Feb;75(2):94–8.
 529. Eisemann N, Waldmann A, Katalinic A. Epidemiology of Breast Cancer - Current Figures and Trends. *Geburtshilfe Frauenheilkd*. 2013 Feb;73(2):130–5.
 530. Chen T, Jansen L, Gondos A, Emrich K, Holleczeck B, Katalinic A, et al. Survival of ovarian cancer patients in Germany in the early 21st century: a period analysis by age, histology, laterality, and stage. *Eur J Cancer Prev*. 2013 Jan;22(1):59–67.
 531. Waldmann A, Schubert D, Katalinic A. Normative data of the EORTC QLQ-C30 for the German population: a population-based survey. *PLoS One*. 2013;8(9):e74149.
 532. Majek O, Gondos A, Jansen L, Emrich K, Holleczeck B, Katalinic A, et al. Sex differences in colorectal cancer survival: population-based analysis of 164,996 colorectal cancer patients in Germany. *PLoS One*. 2013;8(7):e68077.
 533. Listl S, Jansen L, Stenzinger A, Freier K, Emrich K, Holleczeck B, et al. Survival of patients with oral cavity cancer in Germany. *PLoS One*. 2013;8(1):e53415.
 534. Hertrampf K, Wiltfang J, Katalinic A, Timm O, Wenz HJ. Recent trends in incidence and mortality of oral and pharyngeal cancer in Schleswig-Holstein in Northern Germany. *Community Dent Health*. 2012 Dec;29(4):268–73.
 535. Katalinic A, Waldmann A, Weinstock MA, Geller AC, Eisemann N, Greinert R, et al. Does skin cancer screening save lives?: an observational study comparing trends in melanoma mortality in regions with and without screening. *Cancer*. 2012 Nov 1;118(21):5395–402.

536. Schnoor M, Waldmann A, Eberle A, Holleczeck B, Katalinic A. Colorectal cancer incidence in Germany: stage-shift 6 years after implementation of a colonoscopy screening program. *Cancer Epidemiol.* 2012 Oct;36(5):417–20.
537. Rusner C, Bandemer-Greulich U, Engel J, Stegmaier C, Zawinell A, Holleczeck B, et al. Population-based hormone receptor-specific incidence trends of breast cancer in Germany. *Maturitas.* 2012 Oct;73(2):152–7.
538. Jansen L, Gondos A, Eberle A, Emrich K, Holleczeck B, Katalinic A, et al. Cancer survival in Eastern and Western Germany after the fall of the iron curtain. *Eur J Epidemiol.* 2012 Sept;27(9):689–93.
539. Hiripi E, Jansen L, Gondos A, Emrich K, Holleczeck B, Katalinic A, et al. Survival of stomach and esophagus cancer patients in Germany in the early 21st century. *Acta Oncol.* 2012 Sept;51(7):906–14.
540. Eisemann N, Jansen L, Holleczeck B, Waldmann A, Luttmann S, Emrich K, et al. Up-to-date results on survival of patients with melanoma in Germany. *Br J Dermatol.* 2012 Sept;167(3):606–12.
541. Chen T, Jansen L, Gondos A, Emrich K, Holleczeck B, Luttmann S, et al. Survival of cervical cancer patients in Germany in the early 21st century: a period analysis by age, histology, and stage. *Acta Oncol.* 2012 Sept;51(7):915–21.
542. Waldmann A, Nolte S, Geller AC, Katalinic A, Weinstock MA, Volkmer B, et al. Frequency of excisions and yields of malignant skin tumors in a population-based screening intervention of 360,288 whole-body examinations. *Arch Dermatol.* 2012 Aug;148(8):903–10.
543. Majek O, Gondos A, Jansen L, Emrich K, Holleczeck B, Katalinic A, et al. Survival from colorectal cancer in Germany in the early 21st century. *Br J Cancer.* 2012 May 22;106(11):1875–80.
544. Waldmann A, Kapsimalakou S, Katalinic A, Grande-Nagel I, Stoeckelhuber BM, Fischer D, et al. Benefits of the quality assured double and arbitration reading of mammograms in the early diagnosis of breast cancer in symptomatic women. *Eur Radiol.* 2012 May;22(5):1014–22.
545. Perl M, Waldmann A, Pritzkeleit R, Katalinic A. [Temporal changes in quality of life after prostate carcinoma]. *Urologe A.* 2012 May;51(5):706–12.
546. Chen T, Jansen L, Gondos A, Ressing M, Holleczeck B, Katalinic A, et al. Survival of endometrial cancer patients in Germany in the early 21st century: a period analysis by age, histology, and stage. *BMC Cancer.* 2012 Mar 30;12:128.
547. Hertrampf K, Wiltfang J, Katalinic A, Timm O, Wenz HJ. Trends in incidence, tumour sites and tumour stages of oral and pharyngeal cancer in Northern Germany. *J Cancer Res Clin*

Oncol. 2012 Mar;138(3):431–7.

548. Waldmann A, Nolte S, Weinstock MA, Breitbart EW, Eisemann N, Geller AC, et al. Skin cancer screening participation and impact on melanoma incidence in Germany--an observational study on incidence trends in regions with and without population-based screening. *Br J Cancer*. 2012 Feb 28;106(5):970–4.
549. Waldmann A, Adrich S, Eisemann N, Fauteck H, Grande-Nagel I, Schaefer FKW, et al. [Structure and process quality of quality-assured mamma diagnostics in Schleswig-Holstein]. *Rofo*. 2012 Feb;184(2):113–21.
550. Hiripi E, Gondos A, Emrich K, Holleczech B, Katalinic A, Luttmann S, et al. Survival from common and rare cancers in Germany in the early 21st century. *Ann Oncol*. 2012 Feb;23(2):472–9.
551. Breitbart EW, Waldmann A, Nolte S, Capellaro M, Greinert R, Volkmer B, et al. Systematic skin cancer screening in Northern Germany. *J Am Acad Dermatol*. 2012 Feb;66(2):201–11.
552. Hakulinen T, Arbyn M, Brewster DH, Coebergh JW, Coleman MP, Crocetti E, et al. Harmonization may be counterproductive--at least for parts of Europe where public health research operates effectively. *Eur J Public Health*. 2011 Dec;21(6):686–7.
553. Brenner H, Altenhofen L, Katalinic A, Lansdorp-Vogelaar I, Hoffmeister M. Sojourn time of preclinical colorectal cancer by sex and age: estimates from the German national screening colonoscopy database. *Am J Epidemiol*. 2011 Nov 15;174(10):1140–6.
554. Eisemann N, Waldmann A, Katalinic A. Imputation of missing values of tumour stage in population-based cancer registration. *BMC Med Res Methodol*. 2011 Sept 19;11:129.
555. Obi N, Waldmann A, Babaev V, Katalinic A. [Record linkage of a large clinical practice patient cohort with the Cancer Registry Schleswig-Holstein]. *Gesundheitswesen*. 2011 July;73(7):452–8.
556. Dittmer C, Katalinic A, Mundhenke C, Thill M, Fischer D. Epidemiology of vulvar and vaginal cancer in Germany. *Arch Gynecol Obstet*. 2011 July;284(1):169–74.
557. Obi N, Waldmann A, Schäfer F, Schreer I, Katalinic A. Impact of the Quality assured Mamma Diagnostic (QuaMaDi) programme on survival of breast cancer patients. *Cancer Epidemiol*. 2011 June;35(3):286–92.
558. Waldmann A, Nolte S, Pritzkeleit R, Breitbart EW, Katalinic A. Different aspects of self-reported quality of life in 450 german melanoma survivors. *Cancers (Basel)*. 2011 May 11;3(2):2316–32.
559. Waldmann A, Eberle A, Hentschel S, Holleczech B, Katalinic A. [Population-based incidence rates of colorectal neoplasms (2000 - 2006) - has systematic colonoscopy screening an impact on incidence? A combined analysis of cancer registry data of the

- Federal States of Bremen, Hamburg, Saarland and Schleswig-Holstein]. *Z Gastroenterol*. 2010 Dec;48(12):1358–66.
560. Waldmann A, Dreckschmidt J, Pritzkeleit R, Katalinic A. [Test-retest reliability of the OVIS Questionnaire--an instrument to evaluate oncological care from a patient's point of view]. *Gesundheitswesen*. 2010 Oct;72(10):707–13.
 561. Pritzkeleit R, Beske F, Katalinic A. [Disease numbers in pneumology - a projection to 2060]. *Pneumologie*. 2010 Sept;64(9):535–40.
 562. Katalinic A, Peters E, Beske F, Pritzkeleit R. Projection of Morbidity 2030 and 2050: Impact for the National Health System and Blood Supply. *Transfus Med Hemother*. 2010 June;37(3):155–9.
 563. Geller AC, Greinert R, Sinclair C, Weinstock MA, Aitken J, Boniol M, et al. A nationwide population-based skin cancer screening in Germany: proceedings of the first meeting of the International Task Force on Skin Cancer Screening and Prevention (September 24 and 25, 2009). *Cancer Epidemiol*. 2010 June;34(3):355–8.
 564. Schaefer FKW, Waldmann A, Katalinic A, Wefelnberg C, Heller M, Jonat W, et al. Influence of additional breast ultrasound on cancer detection in a cohort study for quality assurance in breast diagnosis--analysis of 102,577 diagnostic procedures. *Eur Radiol*. 2010 May;20(5):1085–92.
 565. Haberland J, Bertz J, Wolf U, Ziese T, Kurth BM. German cancer statistics 2004. *BMC Cancer*. 2010 Feb 22;10:52.
 566. Stang A, Katalinic A, Dieckmann KP, Pritzkeleit R, Stabenow R. A novel approach to estimate the German-wide incidence of testicular cancer. *Cancer Epidemiol*. 2010 Feb;34(1):13–9.
 567. Hug K, Grize L, Seidler A, Kaatsch P, Schüz J. Parental occupational exposure to extremely low frequency magnetic fields and childhood cancer: a German case-control study. *Am J Epidemiol*. 2010 Jan 1;171(1):27–35.
 568. Pritzkeleit R, Beske F, Katalinic A. [Demographic change and cancer]. *Onkologie*. 2010;33 Suppl 7:19–24.
 569. Spix C, Schulze-Rath R, Kaatsch P, Blettner M. Case-control study on risk factors for leukaemia and brain tumours in children under 5 years in Germany. *Klin Padiatr*. 2009 Dec;221(6):362–8.
 570. Spix C, Mergenthaler A, Kaatsch P. [Data exchange between the German Childhood Cancer Registry and the Epidemiological Cancer State Registries]. *Klin Padiatr*. 2009 Dec;221(6):398–9.
 571. Katalinic A, Raspe H, Waldmann A. [Positive family history of colorectal cancer--use of a

- questionnaire]. *Z Gastroenterol*. 2009 Nov;47(11):1125–31.
572. Waldmann A, Raspe H, Katalinic A. [Colon cancer risk in persons at familial or hereditary risk aged < 55 years]. *Z Gastroenterol*. 2009 Oct;47(10):1052–8.
 573. Loerbroeks A, Apfelbacher CJ, Thayer JF, Debling D, Stürmer T. Neuroticism, extraversion, stressful life events and asthma: a cohort study of middle-aged adults. *Allergy*. 2009 Oct;64(10):1444–50.
 574. Ludwig AK, Katalinic A, Entenmann A, Thyen U, Sutcliffe AG, Diedrich K, et al. Can we sense ART? The blinded examiner is not blind-a problem with follow-up studies on children born after assisted reproduction. *Fertil Steril*. 2009 Sept;92(3):950–2.
 575. Waldmann A, Rohde V, Bremner K, Krahn M, Kuechler T, Katalinic A. Measuring prostate-specific quality of life in prostate cancer patients scheduled for radiotherapy or radical prostatectomy and reference men in Germany and Canada using the Patient Oriented Prostate Utility Scale-Psychometric (PORPUS-P). *BMC Cancer*. 2009 Aug 23;9:295.
 576. Stanulla M, Schaeffeler E, Möricke A, Coulthard SA, Cario G, Schrauder A, et al. Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Münster protocols. *Blood*. 2009 Aug 13;114(7):1314–8.
 577. Kaatsch P, Reinisch I, Spix C, Berthold F, Janka-Schaub G, Mergenthaler A, et al. Case-control study on the therapy of childhood cancer and the occurrence of second malignant neoplasms in Germany. *Cancer Causes Control*. 2009 Aug;20(6):965–80.
 578. Kaatsch P, Debling D, Blettner M, Spix C. Second malignant neoplasms after childhood cancer in Germany--results from the long-term follow-up of the German Childhood Cancer Registry. *Strahlenther Onkol*. 2009 Aug;185 Suppl 2:8–10.
 579. Spix C, Blettner M. Re: BAKER P.J. & HOEL D.G. (2007) *European Journal of Cancer Care* 16, 355-363. Meta-analysis of standardized incidence and mortality rates of childhood leukaemia in proximity to nuclear facilities. *Eur J Cancer Care (Engl)*. 2009 July;18(4):429–30.
 580. Hammer GP, Seidenbusch MC, Schneider K, Regulla DF, Zeeb H, Spix C, et al. A cohort study of childhood cancer incidence after postnatal diagnostic X-ray exposure. *Radiat Res*. 2009 Apr;171(4):504–12.
 581. Gatta G, Zigon G, Capocaccia R, Coebergh JW, Desandes E, Kaatsch P, et al. Survival of European children and young adults with cancer diagnosed 1995-2002. *Eur J Cancer*. 2009 Apr;45(6):992–1005.
 582. Schafmayer C, Buch S, Völzke H, von Schönfels W, Egberts JH, Schniewind B, et al. Investigation of the colorectal cancer susceptibility region on chromosome 8q24.21 in a

- large German case-control sample. *Int J Cancer*. 2009 Jan 1;124(1):75–80.
583. Rohde V, Weidner W, Katalinic A. Decrease in prostate cancer incidence and mortality in Germany - effects of opportunistic PSA screening or more? *Urol Int*. 2009;83(2):134–40.
 584. Katalinic A, Pritzkuleit R, Waldmann A. Recent Trends in Breast Cancer Incidence and Mortality in Germany. *Breast Care (Basel)*. 2009;4(2):75–80.
 585. Katalinic A, Lemmer A, Zawinell A, Rawal R, Waldmann A. Trends in hormone therapy and breast cancer incidence - results from the German Network of Cancer Registries. *Pathobiology*. 2009;76(2):90–7.
 586. Debling D, Spix C, Blettner M, Michaelis J, Kaatsch P. The cohort of long-term survivors at the German childhood cancer registry. *Klin Padiatr*. 2008 Dec;220(6):371–7.
 587. Spix C, Spallek J, Kaatsch P, Razum O, Zeeb H. Cancer survival among children of Turkish descent in Germany 1980-2005: a registry-based analysis. *BMC Cancer*. 2008 Nov 28;8:355.
 588. Merzenich H, Schmiedel S, Bennack S, Brüggemeyer H, Philipp J, Blettner M, et al. Childhood leukemia in relation to radio frequency electromagnetic fields in the vicinity of TV and radio broadcast transmitters. *Am J Epidemiol*. 2008 Nov 15;168(10):1169–78.
 589. Pritzkuleit R, Waldmann A, Raspe H, Katalinic A. The population-based oncological health care study OVIS - recruitment of the patients and analysis of the non-participants. *BMC Cancer*. 2008 Oct 27;8:311.
 590. Laengler A, Spix C, Seifert G, Gottschling S, Graf N, Kaatsch P. Complementary and alternative treatment methods in children with cancer: A population-based retrospective survey on the prevalence of use in Germany. *Eur J Cancer*. 2008 Oct;44(15):2233–40.
 591. Kaatsch P, Spix C, Jung I, Blettner M. Childhood leukemia in the vicinity of nuclear power plants in Germany. *Dtsch Arztebl Int*. 2008 Oct;105(42):725–32.
 592. Heywang-Köbrunner SH, Schreer I, Heindel W, Katalinic A. Imaging studies for the early detection of breast cancer. *Dtsch Arztebl Int*. 2008 Aug;105(31–32):541–7.
 593. Beelte AK, Pritzkuleit R, Katalinic A. [Lung cancer incidence and mortality: current trends and projections based on data from Schleswig-Holstein]. *Dtsch Med Wochenschr*. 2008 July;133(28–29):1487–92.
 594. Spallek J, Spix C, Zeeb H, Kaatsch P, Razum O. Cancer patterns among children of Turkish descent in Germany: a study at the German Childhood Cancer Registry. *BMC Public Health*. 2008 May 7;8:152.
 595. Waldmann A, Pritzkuleit R, Raspe H, Katalinic A. Guideline-compatible treatment of breast cancer patients: the status quo in schleswig-holstein. *Dtsch Arztebl Int*. 2008 May;105(18):337–43.

596. Pommerening K, Debling D, Kaatsch P, Blettner M. [Registries for rare diseases. Compliance and data protection]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2008 May;51(5):491–9.
597. Spix C, Eletr D, Blettner M, Kaatsch P. Temporal trends in the incidence rate of childhood cancer in Germany 1987-2004. Int J Cancer. 2008 Apr 15;122(8):1859–67.
598. Reinhard H, Reinert J, Beier R, Furtwängler R, Alkasser M, Rutkowski S, et al. Rhabdoid tumors in children: prognostic factors in 70 patients diagnosed in Germany. Oncol Rep. 2008 Mar;19(3):819–23.
599. Kaatsch P, Spix C, Schulze-Rath R, Schmiedel S, Blettner M. Leukaemia in young children living in the vicinity of German nuclear power plants. Int J Cancer. 2008 Feb 15;122(4):721–6.
600. Weihkopf T, Blettner M, Dantonello T, Jung I, Klingebiel T, Koscielniak E, et al. Incidence and time trends of soft tissue sarcomas in German children 1985-2004 - a report from the population-based German Childhood Cancer Registry. Eur J Cancer. 2008 Feb;44(3):432–40.
601. Katalinic A, Rawal R. Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res Treat. 2008 Feb;107(3):427–30.
602. Hüppe D, Hartmann H, Felten G, Kemen M, Tannapfel A, Gillessen A, et al. [Effectiveness of screening colonoscopy in a community-based study]. Z Gastroenterol. 2008 Feb;46(2):193–200.
603. Spix C, Schmiedel S, Kaatsch P, Schulze-Rath R, Blettner M. Case-control study on childhood cancer in the vicinity of nuclear power plants in Germany 1980-2003. Eur J Cancer. 2008 Jan;44(2):275–84.
604. Borgmann A, Zinn C, Hartmann R, Herold R, Kaatsch P, Escherich G, et al. Secondary malignant neoplasms after intensive treatment of relapsed acute lymphoblastic leukaemia in childhood. Eur J Cancer. 2008 Jan;44(2):257–68.
605. Kaatsch P, Mergenthaler A. Incidence, time trends and regional variation of childhood leukaemia in Germany and Europe. Radiat Prot Dosimetry. 2008;132(2):107–13.
606. Waldmann A, Lautz E, Hampe J, Schreiber S, Schafmayer C, Katalinic A. [Utilization of inpatient rehabilitation of younger patients with colorectal neoplasms--results of the project 'Popgen-colorectal cancer']. Rehabilitation (Stuttg). 2007 Dec;46(6):349–55.
607. Gosepath J, Spix C, Talebloo B, Blettner M, Mann WJ. Incidence of childhood cancer of the head and neck in Germany. Ann Oncol. 2007 Oct;18(10):1716–21.
608. Schafmayer C, Buch S, Egberts JH, Franke A, Brosch M, El Sharawy A, et al. Genetic investigation of DNA-repair pathway genes PMS2, MLH1, MSH2, MSH6, MUTYH,

- OGG1 and MTH1 in sporadic colon cancer. *Int J Cancer*. 2007 Aug 1;121(3):555–8.
609. Schüz J, Forman MR. Birthweight by gestational age and childhood cancer. *Cancer Causes Control*. 2007 Aug;18(6):655–63.
 610. Waldmann A, Pritzkeleit R, Raspe H, Katalinic A. The OVIS study: health related quality of life measured by the EORTC QLQ-C30 and -BR23 in German female patients with breast cancer from Schleswig-Holstein. *Qual Life Res*. 2007 June;16(5):767–76.
 611. Svendsen AL, Weihkopf T, Kaatsch P, Schüz J. Exposure to magnetic fields and survival after diagnosis of childhood leukemia: a German cohort study. *Cancer Epidemiol Biomarkers Prev*. 2007 June;16(6):1167–71.
 612. Schüz J, Weihkopf T, Kaatsch P. Medication use during pregnancy and the risk of childhood cancer in the offspring. *Eur J Pediatr*. 2007 May;166(5):433–41.
 613. Waldmann A, Lautz E, Hampe J, Schreiber S, Schafmayer C, Raspe H, et al. [Description of the medical care of younger patients (<65 years) with colorectal cancer in Schleswig-Holstein--are diagnostics and therapy compliant with the actual S3-guidelines?]. *Gesundheitswesen*. 2007 Apr;69(4):216–23.
 614. Katalinic A, Bartel C, Raspe H, Schreer I. Beyond mammography screening: quality assurance in breast cancer diagnosis (The QuaMaDi Project). *Br J Cancer*. 2007 Jan 15;96(1):157–61.
 615. Selle B, Furtwängler R, Graf N, Kaatsch P, Bruder E, Leuschner I. Population-based study of renal cell carcinoma in children in Germany, 1980-2005: more frequently localized tumors and underlying disorders compared with adult counterparts. *Cancer*. 2006 Dec 15;107(12):2906–14.
 616. Spallek J, Kaatsch P, Spix C, Ulusoy N, Zeeb H, Razum O. [Name-based identification of cases of Turkish origin in the childhood cancer registry in Mainz]. *Gesundheitswesen*. 2006 Oct;68(10):643–9.
 617. Spix C, Pastore G, Sankila R, Stiller CA, Steliarova-Foucher E. Neuroblastoma incidence and survival in European children (1978-1997): report from the Automated Childhood Cancer Information System project. *Eur J Cancer*. 2006 Sept;42(13):2081–91.
 618. Magnani C, Pastore G, Coebergh JW, Viscomi S, Spix C, Steliarova-Foucher E. Trends in survival after childhood cancer in Europe, 1978-1997: report from the Automated Childhood Cancer Information System project (ACCIS). *Eur J Cancer*. 2006 Sept;42(13):1981–2005.
 619. Kaatsch P, Steliarova-Foucher E, Crocetti E, Magnani C, Spix C, Zambon P. Time trends of cancer incidence in European children (1978-1997): report from the Automated Childhood Cancer Information System project. *Eur J Cancer*. 2006 Sept;42(13):1961–71.

620. Stang A, Streller B, Katalinic A, Lehnert M, Eisinger B, Kaatsch P, et al. Incidence of skin lymphoma in Germany. *Ann Epidemiol.* 2006 Mar;16(3):214–22.
621. Rohde V, Diemer T, Hauck E, Bestmann B, Miller J, Schröder H, et al. Prescription practice for LH-RH analogs and androgen receptor antagonists in the treatment of advanced prostate cancer in Germany (1993-2003). *Urol Int.* 2006;77(4):311–6.
622. Minkov M, Prosch H, Steiner M, Grois N, Pötschger U, Kaatsch P, et al. Langerhans cell histiocytosis in neonates. *Pediatr Blood Cancer.* 2005 Nov;45(6):802–7.
623. Kaatsch P. [What happens after cancer in children?]. *Dtsch Med Wochenschr.* 2005 Oct 28;Suppl 1:68.
624. Lehnert M, Eberle A, Hentschel S, Katalinic A, Kieschke J, Schmidtman I, et al. [Malignant melanoma of the skin as evidenced by epidemiological cancer registries in Germany -- incidence, clinical parameters, variations in recording]. *Gesundheitswesen.* 2005 Oct;67(10):729–35.
625. Steliarova-Foucher E, Stiller C, Kaatsch P, Berrino F, Coebergh JW. Trends in childhood cancer incidence in Europe, 1970-99. *Lancet.* 2005 June 18;365(9477):2088.
626. Gatta G, Capocaccia R, Stiller C, Kaatsch P, Berrino F, Terenziani M. Childhood cancer survival trends in Europe: a EURO CARE Working Group study. *J Clin Oncol.* 2005 June 1;23(16):3742–51.
627. Kaatsch P, Blettner M, Spix C, Jürgens H. [Follow up of long-term survivors after childhood cancer in Germany]. *Klin Padiatr.* 2005 June;217(3):169–75.
628. Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification of Childhood Cancer, third edition. *Cancer.* 2005 Apr 1;103(7):1457–67.
629. Steliarova-Foucher E, Stiller C, Kaatsch P, Berrino F, Coebergh JW, Lacour B, et al. Geographical patterns and time trends of cancer incidence and survival among children and adolescents in Europe since the 1970s (the ACCISproject): an epidemiological study. *Lancet.* 2004 Dec 11;364(9451):2097–105.
630. Katalinic A, Rösch C, Ludwig M. Pregnancy course and outcome after intracytoplasmic sperm injection: a controlled, prospective cohort study. *Fertil Steril.* 2004 June;81(6):1604–16.
631. Katalinic A. [Population-based cancer registration in Germany. Essentials and perspectives]. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz.* 2004 May;47(5):422–8.
632. Kaatsch P. [German Childhood Cancer Registry and its favorable setting]. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz.* 2004 May;47(5):437–43.
633. Katalinic A, Kunze U, Schäfer T. Epidemiology of cutaneous melanoma and non-melanoma skin cancer in Schleswig-Holstein, Germany: incidence, clinical subtypes, tumour stages

- and localization (epidemiology of skin cancer). *Br J Dermatol*. 2003 Dec;149(6):1200–6.
634. Spix C, Michaelis J, Berthold F, Erttmann R, Sander J, Schilling FH. Lead-time and overdiagnosis estimation in neuroblastoma screening. *Stat Med*. 2003 Sept 30;22(18):2877–92.
635. Katalinic A, Holzmann M, Kunze U. [Relation of breast cancer tumour stage and the degree of registration in a population-based cancer registry]. *Gesundheitswesen*. 2003 Sept;65(8–9):509–15.
636. Schilling FH, Spix C, Berthold F, Erttmann R, Sander J, Treuner J, et al. Children may not benefit from neuroblastoma screening at 1 year of age. Updated results of the population based controlled trial in Germany. *Cancer Lett*. 2003 July 18;197(1–2):19–28.
637. Berthold F, Hero B, Kremens B, Handgretinger R, Henze G, Schilling FH, et al. Long-term results and risk profiles of patients in five consecutive trials (1979-1997) with stage 4 neuroblastoma over 1 year of age. *Cancer Lett*. 2003 July 18;197(1–2):11–7.
638. Schüz J, Morgan G, Böhler E, Kaatsch P, Michaelis J. Atopic disease and childhood acute lymphoblastic leukemia. *Int J Cancer*. 2003 June 10;105(2):255–60.
639. Tannapfel A, Sommerer F, Benicke M, Katalinic A, Uhlmann D, Witzigmann H, et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. *Gut*. 2003 May;52(5):706–12.
640. Klein G, Michaelis J, Spix C, Wibbing R, Eggers G, Ritter J, et al. Second malignant neoplasms after treatment of childhood cancer. *Eur J Cancer*. 2003 Apr;39(6):808–17.
641. Rohde V, Wellmann A, Fogt F, Weidner W, Katalinic A. Economical data and advanced prostate carcinoma: do we need new guidelines for decision making? *Oncol Rep*. 2002 Dec;9(6):1185–8.
642. Burkhardt-Hammer T, Spix C, Brenner H, Kaatsch P, Berthold F, Hero B, et al. Long-term survival of children with neuroblastoma prior to the neuroblastoma screening project in Germany. *Med Pediatr Oncol*. 2002 Sept;39(3):156–62.
643. Tannapfel A, Sommerer F, Benicke M, Weinans L, Katalinic A, Geissler F, et al. Genetic and epigenetic alterations of the INK4a-ARF pathway in cholangiocarcinoma. *J Pathol*. 2002 Aug;197(5):624–31.
644. Schüz J, Kaatsch P. Epidemiology of pediatric tumors of the central nervous system. *Expert Rev Neurother*. 2002 July;2(4):469–79.
645. Schilling FH, Spix C, Berthold F, Erttmann R, Fehse N, Hero B, et al. Neuroblastoma screening at one year of age. *N Engl J Med*. 2002 Apr 4;346(14):1047–53.
646. Kaatsch P, Rickert CH, Kühl J, Schüz J, Michaelis J. Population-based epidemiologic data on brain tumors in German children. *Cancer*. 2001 Dec 15;92(12):3155–64.

647. Jaeger W, Ackermann S, Kessler H, Katalinic A, Lang N. The effect of bowel resection on survival in advanced epithelial ovarian cancer. *Gynecol Oncol.* 2001 Nov;83(2):286–91.
648. Tannapfel A, Busse C, Weinans L, Benicke M, Katalinic A, Geissler F, et al. INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas. *Oncogene.* 2001 Oct 25;20(48):7104–9.
649. Brenner H, Kaatsch P, Burkhardt-Hammer T, Harms DO, Schrappe M, Michaelis J. Long-term survival of children with leukemia achieved by the end of the second millennium. *Cancer.* 2001 Oct 1;92(7):1977–83.
650. Spix C, Aareleid T, Stiller C, Magnani C, Kaatsch P, Michaelis J. Survival of children with neuroblastoma. time trends and regional differences in Europe, 1978--1992. *Eur J Cancer.* 2001 Apr;37(6):722–9.
651. Schüz J, Grigat JP, Brinkmann K, Michaelis J. Residential magnetic fields as a risk factor for childhood acute leukaemia: results from a German population-based case-control study. *Int J Cancer.* 2001 Mar 1;91(5):728–35.
652. Schüz J, Kaletsch U, Kaatsch P, Meinert R, Michaelis J. Risk factors for pediatric tumors of the central nervous system: results from a German population-based case-control study. *Med Pediatr Oncol.* 2001 Feb;36(2):274–82.
653. Schilling FH, Berthold F, Erttmann R, Michaelis J, Spix C, Sander J, et al. Population-based and controlled study to evaluate neuroblastoma screening at one year of age in Germany: interim results. *Med Pediatr Oncol.* 2000 Dec;35(6):701–4.
654. von Kries R, Grunert VP, Kaletsch U, Michaelis J, Göbel U. Prevention of childhood leukemia by BCG vaccination in newborns? A population-based case-control study in Lower Saxony, Germany. *Pediatr Hematol Oncol.* 2000 Nov;17(7):541–50.
655. Tannapfel A, Benicke M, Katalinic A, Uhlmann D, Köckerling F, Hauss J, et al. Frequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver. *Gut.* 2000 Nov;47(5):721–7.
656. Tannapfel A, Grund D, Katalinic A, Uhlmann D, Köckerling F, Haugwitz U, et al. Decreased expression of p27 protein is associated with advanced tumor stage in hepatocellular carcinoma. *Int J Cancer.* 2000 July 20;89(4):350–5.
657. Löning L, Zimmermann M, Reiter A, Kaatsch P, Henze G, Riehm H, et al. Secondary neoplasms subsequent to Berlin-Frankfurt-Münster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy. *Blood.* 2000 May 1;95(9):2770–5.
658. Tannapfel A, Weinans L, Geissler F, Schütz A, Katalinic A, Köckerling F, et al. Mutations of p53 tumor suppressor gene, apoptosis, and proliferation in intrahepatic cholangiocellular carcinoma of the liver. *Dig Dis Sci.* 2000 Feb;45(2):317–24.

659. Michaelis J, Kaletsch U, Kaatsch P. [Epidemiology of childhood brain tumors]. *Zentralbl Neurochir.* 2000;61(2):80–7.
660. Katalinic A, Bartel C, Uhlenkamp T, Raspe H. [Developing a small-area cancer atlas: process, validity and possible applications]. *Gesundheitswesen.* 1999 Sept;61(8–9):436–8.
661. Tannapfel A, Wasner M, Krause K, Geissler F, Katalinic A, Hauss J, et al. Expression of p73 and its relation to histopathology and prognosis in hepatocellular carcinoma. *J Natl Cancer Inst.* 1999 July 7;91(13):1154–8.
662. Tannapfel A, Engeland K, Weinans L, Katalinic A, Hauss J, Mössner J, et al. Expression of p73, a novel protein related to the p53 tumour suppressor p53, and apoptosis in cholangiocellular carcinoma of the liver. *Br J Cancer.* 1999 June;80(7):1069–74.
663. Tannapfel A, Geissler F, Köckerling F, Katalinic A, Hauss J, Wittekind C. Apoptosis and proliferation in relation to histopathological variables and prognosis in hepatocellular carcinoma. *J Pathol.* 1999 Mar;187(4):439–45.
664. Tannapfel A, Nüsslein S, Fietkau R, Katalinic A, Köckerling F, Wittekind C. Apoptosis, proliferation, bax, bcl-2 and p53 status prior to and after preoperative radiochemotherapy for locally advanced rectal cancer. *Int J Radiat Oncol Biol Phys.* 1998 June 1;41(3):585–91.
665. Tannapfel A, Nüsslein S, Katalinic A, Köckerling F, Wittekind C, Fietkau R. [Proliferation and apoptosis before and after preoperative simultaneous radiochemotherapy of rectal carcinomas]. *Strahlenther Onkol.* 1998 June;174(6):295–9.
666. Fehm T, Maimonis P, Katalinic A, Jäger WH. The prognostic significance of c-erbB-2 serum protein in metastatic breast cancer. *Oncology.* 1998 Feb;55(1):33–8.
667. Tannapfel A, Katalinic A, Köckerling F, Wittekind C. The prediction of lymph node metastases in colorectal cancer by expression of the nucleoside diphosphate kinase/nm23-H1 and histopathological variables. *Am J Gastroenterol.* 1997 July;92(7):1182–6.
668. Lang E, Katalinic A, Sittl R, Dittner J, Erbe KH, Lang C, et al. [Outpatient management of chronic pain in Middle Franconia]. *Schmerz.* 1997 Apr 18;11(2):101–7.
669. Tannapfel A, Hahn HA, Katalinic A, Fietkau RJ, Kühn R, Wittekind CW. Incidence of apoptosis, cell proliferation and P53 expression in renal cell carcinomas. *Anticancer Res.* 1997 Apr;17(2A):1155–62.
670. Fehm T, Maimonis P, Weitz S, Teramoto Y, Katalinic A, Jäger W. Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients. *Breast Cancer Res Treat.* 1997 Mar;43(1):87–95.
671. Seegenschmiedt MH, Klautke G, Walther E, Feldmann HJ, Katalinic A, Stuschke M, et al. [Water-filtered infrared-A-hyperthermia combined with radiotherapy in advanced and recurrent tumors. Initial results of a multicenter phase I-II study]. *Strahlenther Onkol.* 1996

Sept;172(9):475–84.

672. Tannapfel A, Hahn HA, Katalinic A, Fietkau RJ, Kühn R, Wittekind CW. Prognostic value of ploidy and proliferation markers in renal cell carcinoma. *Cancer*. 1996 Jan 1;77(1):164–71.
673. Tannapfel A, Köckerling F, Katalinic A, Wittekind C. Expression of nm23-H1 predicts lymph node involvement in colorectal carcinoma. *Dis Colon Rectum*. 1995 June;38(6):651–4.